## **Children with Cancer UK**
Trustees’ Report and Financial Statements for the year ended 31 December 2021
Registered Charity Number: 298405 Inaugurated by Diana, Princess of Wales Company limited by guarantee, Number: 4960054
1
## **Children with Cancer UK in numbers**
**Research -** We’re committed to improving survival and finding kinder treatments for children and young people with cancer
## **£800k**
invested into vital, life-saving research
## **2**
new research grants were awarded
## **£1m**
donated to Birmingham Women’s and Children’s Hospital Charity, in
partnership with KwikFit, to provide a high-throughput sequencing machine to support their expansion of cancer and rare disease genetic testing
**Supporting families –** We help children with cancer and their families through the hardships of a cancer diagnosis
## **227**
families attended our virtual parties
## **£200K**
helping children cope with cancer treatment through receiving beads from Beads of Courage UK, our partner charity
**Awareness –** We shine a spotlight on the impact of cancer on children and young people and their families
## **Millions**
of people reached through our campaigns
## **600**
online articles
## **130**
mentions of the charity in printed media
## **8**
families told their childhood cancer stories
2
## **CHILDREN WITH CANCER UK**
## **TRUSTEES’ ANNUAL REPORT AND CONSOLIDATED FINANCIAL STATEMENTS**
## **FOR THE YEAR ENDED 31 DECEMBER 2021**
|**MESSAGE FROM THE CHAIR AND CEO OF**|**04 – 05**|
|---|---|
|**CHILDREN WITH CANCER UK**||
|**OUTCOMES IN 2021**|**06**|
|**RESEARCH OUTCOMES IN 2021**|**07 – 10**|
|**SUPPORTING FAMILIES IN 2021**|**11 – 12**|
|**AWARENESS ACTIVITIES IN 2021**|**13**|
|**FUNDRAISING HIGHLIGHTS AND COMPLIANCE**|**14 – 17**|
|**THANK YOU**|**18**|
|**FINANCIAL REVIEW**|**19 – 30**|
|**STRATEGIC PLANS**|**22 – 23**|
|**GOING CONERN, RISKS & GOVERNANCE**|**23 – 30**|
|**REFERENCE AND ADMINISTRATION**|**31 – 32**|
|**STATEMENT OF TRUSTEES’ RESPONSIBILITIES**|**33**|
|**INDEPENDENT AUDITORS’ REPORT**|**34 – 37**|
|**CONSOLIDATED FINANCIAL STATEMENTS**|**38 – 40**|
|**NOTES TO THE FINANCIAL STATEMENTS**|**41 – 58**|
3
## **MESSAGE FROM THE CHAIR OF CHILDREN WITH CANCER UK**
Welcome to our Annual Report and Accounts for 2021.
## **Welcome from Chair of Trustees**
Firstly, I would like to thank Eddie and Cliff O’Gorman. Eddie has stepped down as Chairman - having set up the charity with his wife Marion in 1988. They built the charity as a promise to their son Paul, who died from leukaemia, that they would raise funds for children with cancer. This wonderful legacy, built from a family tragedy, is one that continues to support families going through similar experiences today. Thank you to Cliff also for all he has done alongside Eddie, since the charity was created over 30 years ago, their hard work and dedication has established it as the leading children's charity dedicated to fighting childhood cancer.
We are entering a new chapter of our journey and, with that, I am delighted to welcome Jo Elvin, our new CEO who will be a fantastic asset to the charity bringing a wealth of experience, drive and determination. We are looking forward to her working closely with our various teams to ensure that we continue to build on the fantastic work the O’Gorman family started.
Despite the inevitable challenges COVID-19 created I am proud of the resilience the charity has demonstrated. Our ability to embrace a more digital approach enabled the charity to weather the storm but also ensures we are well placed for further growth in the future. That along with our solid foundations also ensured we were able to honour existing funding commitments despite the unprecedented times we faced.
I’d like to take this opportunity to extend my gratitude to all the volunteers, supporters, collaborators, associations, researchers, corporates and the brilliant team at Children with Cancer UK for continuing to work hard to raise money, awareness and offer support to help the charity continue its research funding and support families affected by childhood cancer.
I would also like to thank my fellow trustees for their time, experience and dedication, working together with me to ensure the charity goes from strength to strength.
We are proud of our strong track record of working with other cancer charities demonstrating the clear impact joint funding can have on survival rates and improvements in treatment. We have made great progress collaborating with organisations including Teenage Cancer Trust and Young Lives Vs Cancer. We are also delighted to continue to work alongside Cancer Research UK on the Cancer Research UK-Children with Cancer UK Innovation Awards, now into its second year of funding. Another collaboration we are looking forward to in 2022 / 2023 is with the Bone Cancer Research Trust. We are funding a £1 million research programme that will look into a rare cancer that has not had survival improvements for four decades.
4
These are just a few of the areas in which we are making great strides as we continue to look to deliver our vision of a world where every child survives cancer.
We could not do what we do without the continued loyalty and unwavering support of every donor, thank you for every single penny. It is making a difference now and will do for years to come.
## **David Gibbs Chair of Trustees Children with Cancer UK**
## **Welcome from CEO of Children with Cancer UK**
It is a privilege to step into my new role as the CEO of Children with Cancer UK. The O’Gorman family have built an organisation that has been saving young lives for decades. They leave a huge legacy and one I am committed to protecting and ensuring continues for decades to come. The charity has been doing outstanding work for over thirty years leading the way in childhood cancer research and supporting children, young people and their families when they are at their most vulnerable. Our vision remains a world where every child survives cancer and together with my team we will continue to strive towards that, delivering our mission to ensure we improve the lives of those suffering with childhood cancer now and in the future.
Unfortunately, I know there are very few people who are not touched in some way by the devastating effects of cancer. I have the greatest admiration and respect for every person it comes into contact with, whether they have been diagnosed themselves or are working to find a cure. Knowing only too well how important pastoral care is to support families I am keen that we continue to help with emotional support as well as the logistics around dealing with the traumatic experience of finding out that your child has cancer.
The continued success of the charity, which has continued despite the adverse effects experienced due to the pandemic, is due to the passion of all those involved including donors, fundraisers, volunteers and dedicated team members. The charity’s successful track record of alliances with several partner organisations and fellow charities is also something I am keen we continue to grow. I believe these collaborations, bringing together vital specialist knowledge and skills will play a vital role in delivering further life-changing results through research.
It’s only thanks to our supporters that we can continue our vital work. Thank you so very much for your continued support.
## **Jo Elvin**
## **CEO of Children with Cancer UK**
5
## **OUTCOMES IN 2021**
How donations have helped children and young people with cancer.
We are pleased to announce that in 2021 we raised £14.8m to fund specialist childhood cancer research and support families.
For every £1 we spend on fundraising, we raised £6 more
For every £1 donated we spend
- 80p on fighting childhood cancer
- 30p on research projects,
- 29p on supporting families,
- 21p on raising awareness,
- 20p on raising more money
We receive no government funding and rely exclusively on the generosity of our supporters
6
## **OUR YEAR IN RESEARCH**
Around 1,800 children and 2,400 young people are diagnosed with cancer each year in the United Kingdom. Whilst over 80% of patients survive, cancer remains the leading disease related cause of death for children under 15 years of age. From the time of their diagnosis, children and young people endure difficult treatments to eradicate their disease, with potentially life-altering side effects on their development. High-quality and impactful research is essential to driving forward our vision of a world where every child survives cancer. Research has significantly contributed to the improvements seen in childhood cancer survival rates from 67.3% in 1990 to a predicted 85.5% in 2018. Improved treatments and understanding of the disease are important in the fight against cancer. Only around 2% of cancer research funding in the UK is spent on research that is fully dedicated to childhood and young adult cancer.
Children with Cancer UK plays a major role in funding vital life-saving research. We are dedicated to improving survival rates across all types of childhood cancer, improving the quality of life in young cancer survivors and finding less-toxic treatment options. As the UK’s leading charity dedicated to childhood cancer research, we are proud of our contribution to the ongoing breakthroughs which continue to help save thousands of young lives.
The COVID-19 pandemic continued to have a significant impact on research in the UK and result in delays for many existing research projects. As a result of the COVID-19 pandemic we were limited in our efforts to fund new research projects. Despite these limitations, we funded 2 new research projects in 2021, worth over £800k. These projects aim to develop effective treatment strategies and improve the long-term health outcomes for children, teenagers and young adults diagnosed with cancer.
Combined with existing active research grants, this means that we are now funding a total of 52 projects, worth over £16 million across the UK and abroad. Our funding is helping more children survive cancer and look forward to longer and healthier lives after their treatment has ended.
In 2021 we provided over £1 million as an infrastructure grant to Birmingham Women’s and Children’s Hospital Charity, in partnership with KwikFit, to provide a high-throughput sequencing machine (NovaSeq 6000) to support the expansion of cancer and rare disease genetic testing at the West Midlands Regional Genetic Laboratory.
Children with Cancer UK values its partnerships with others in the paediatric and young adult cancer community including the National Cancer Research Institute (NCRI) and the Association of Medical Research Charities (AMRC). Our research funding including other charities, government funders, cancer organizations and universities. We supported several conferences including the British Neuro-oncology Society (BNOS) annual meeting and the International Nursing Association Conference. These collaborative events during the year help to facilitate innovation and share specialist expertise.
7
In development with members of the Scientific Advisory Panel (SAP) and consultation with partners and stakeholders, 2021 saw the refresh of the research strategy which outlines our overarching research aims for the next five years.
## **Research Strategy**
The refreshed Children with Cancer UK research strategy outlines our aims and objectives for the next five years, provides insights into what we hope to achieve and how funding can be used to help more children and young people survive cancer. The strategy was developed with insights from the Cancer Research Database (CaRD), engagement with research partners, reviews of the research landscape and guidance from the SAP.
Our research program is designed to progress our principal aims. First, we wish to develop improved treatments so that more patients are cured with less toxic side effects. Second, we wish to better understand how cancer develops so that one day we may be able to prevent it.
Children with Cancer UK’s research objectives include the development of more effective treatments including immunotherapies and tailored treatments which target cancer-specific molecular changes targeted with reduced toxicity. The identification of improved diagnostic and prognostic biomarkers to allow accurate diagnosis and disease monitoring. The early identification and mitigation of treatment related toxicity. The further understanding of cellular and molecular oncogenesis and the promotion and dissemination of research findings to achieve maximum research impact.
As a charity we are committed to working in partnership with patients and the public, we recognize the valuable insight this involvement can provide. We also understand the need to invest in early-career researchers. In future, we hope to support the next generation of clinician scientists and research leaders, champion their long-term career progression through our fellowship and clinical studentship programs and prepare them to make substantial contributions to improving outcomes for children with cancer.
8
## **New research awards**
In 2021 we funded 2 new research projects worth over £800k.
## INSTINCT-MB: Strategic implementation of novel combination therapeutics for high-risk medulloblastoma, Professor Steve Clifford, Newcastle University
One of the major specific challenges in childhood cancer is Group 3 medulloblastoma driven by the over-abundance of a gene called MYC (MYC-MBGroup3). This tumour group occurs almost exclusively in young children and is essentially incurable, contributing significantly to overall childhood cancer death rates. New targeted treatments are urgently needed to improve the outlook for children with high-risk medulloblastoma. The INSTINCT-MB project co-funded by Blue Skye Thinking and Little Hero will seek to develop new treatments for MYC-MBGroup3, using new drugs and promising new immunotherapies known as Chimeric Antigen Receptor T- cells (CAR-T) therapies.
Brain tumours are the most common tumours that develop in children. Medulloblastoma is the most common malignant brain tumour affecting children. Over the last 50 years, advances in standard treatments such as surgery, radiotherapy and chemotherapy have led to long-term survival rates of approximately 70%. However, survival rates have plateaued, and current therapies are associated with significant long-term side effects in surviving patients. New therapies are urgently required to improve the outlook for children with high-risk medulloblastoma.
Professor Steve Clifford and his team have developed a series of experimental models which recapitulate the disease in children as closely as possible. Using these models, they will develop a deep understanding of the biological vulnerabilities of these tumours. Based on these findings, they will further develop and deliver new MYC-targeting drug and CAR-T treatments, test regimens for administration, and generate the essential evidence required to directly translate this work into clinical studies in children with medulloblastoma. Knowledge gained from preclinical trials will track how tumours respond to treatment, identifying potential mechanisms of treatment resistance.
The team anticipate the treatment approaches developed by this project will help to reduce the incidence of disease relapse and the late-effects associated with current standard of care treatments for children with relapsed medulloblastoma and treatment-resistant MYC-driven medulloblastomas.
Bioinformatics support for primary bone cancer plus other childhood cancer studies, Dr Darrell Greene, University of East Anglia.
9
Osteosarcoma (OS) is a devastating primary bone cancer mainly occurring in children, teenagers and young adults. There are around 52,000 new cases per year worldwide. Five-year survival, i.e. patients still alive 5 years after their initial diagnosis (but they may still have OS), is extremely poor at 40%. A major clinical complication in primary bone cancer is rapid spread of disease to the lungs. Metastasis causes more than 90% of patient death. The central theme of this project is to extensively understand metastatic OS at the molecular/cellular level in order to detect targets or opportunities for therapy.
Scientists will download data from several experiments and then use sophisticated methods to understand the “real life” events that underpin the data. This is extremely important to understand how cancer works –so that we can detect and fix abnormalities in cancer cells whilst not affecting healthy cells.
## **Expansion of cancer and rare disease genetic testing**
Genomic testing for patients diagnosed with cancer is incredibly important and over the last decade, large scale sequencing projects have identified pertinent DNA changes, which have enabled scientists to develop new and improved cancer drugs and treatments to specifically target these variations. Sequencing all possible DNA changes in a single test gives scientists the best possible chance of detecting the genetic changes driving a child’s cancer; and knowing the genetic makeup of a child or young person’s cancer, or tumour, allows clinicians to offer a more tailored treatment.
The West Midlands Regional Genetic Laboratory (WMRGL), based at Birmingham Women’s and Children’s NHS Foundation Trust, uses the most up-to-date technologies and equipment to provide cancer and rare disease genetic services for patients across the West Midlands, Oxfordshire and Wessex (WMOW). With more than 200 scientific, technical and support staff, it is the largest genetics laboratory in the UK providing services for up to 20% of the UK population.
Our infrastructure grant worth over £1 million purchased the NovaSeq 6000, a state-of-the-art piece of DNA sequencing equipment. This grant has enabled the rapid expansion of cancer genetic testing and will enhance our ability to identify diagnostic and prognostic biomarkers for childhood and young people’s cancers, thereby enabling the development of more-effective and less-toxic treatments for children and young people with cancer.
Initial forecasts provided by NHS England and NHS Trusts across the West Midlands, Oxfordshire and parts of Southern England suggest that approximately 560 children and young people per year could benefit from large cancer panel genetic testing following the installation of the NovaSeq.
10
## **SUPPORTING FAMILIES IN 2021**
At Children with Cancer UK we continue to prioritise keeping families together and providing much needed support to children, young people and their families during challenging times. Despite difficulties meeting together we hosted virtual events for our families throughout the year, giving them happier memories and a welcome respite from the daily worries cancer brings.
## **Building Strength and Courage through beading**
2021 which saw the continuation of our partnership with Beads of Courage UK. Our funding helps to support children and their families through some of the toughest times in their lives through positive coping strategies by helping children to visualize and articulate their experiences through a process called beading. Ongoing research has found that the program helps alleviate treatment induced stress and anxiety, benefitting a child’s mental health and wellbeing.
## **Amazing days out for families affected by childhood cancer**
Ongoing COVID-19 restrictions resulted in us having to cancel all our amazing days out for the second year running. Instead we built on the success of the virtual parties we hosted in 2020 and created more family friendly virtual activities. We are delighted that 227 families were able to join us at these events.
Here follows a snapshot of our much-loved events that allow families to enjoy quality time together and a break from the daily stresses of a childhood cancer diagnosis.
## **Mother’s Day Baking Party**
On Sunday 14th of March we held a very special Baking Party for Mother’s Day for 67 families. Each family received a baking kit in the post to create chocolate shortbread biscuits, and joined together to receive a live cooking tutorial. We then finished with a mini treasure hunt and true and false game.
## **Spring Craft Party**
We had a morning of creating Spring themed crafts in April, and were joined by 76 children affected by childhood cancer, and their families. Our virtual party was hosted by Lexy at Made by Me Craft Parties, and the participants were kept entertained by crafting their very own bunny dream catchers, flower bookmarks and bunny ornaments.
## _**Erin took part in the crafting with her big sister Milla. Her mum, Alexis, told us:**_
Thank you so much for another fabulous craft party! The girls love the oh-so-cute decorations – it’s definitely starting to feel like Spring. These events have really kept us going as we found our feet post-treatment, and given the girls something to look forward to. Erin missed out on so much due to her treatment and COVID-19 meant we couldn’t start giving her the usual childhood experiences when treatment finished. We really appreciate the effort Children with Cancer UK put into finding online ways of generating moments of joy and normality.
11
## **Super Science Slime Party**
In May we held a virtual Science party with Einstein’s Entertainers for children affected by cancer and their families.
60 families signed up to join the online party where they played party games and got involved in fun scientific experiments. A few of the experiments included slime making and helicopter making. All of the children received a mini home lab kit in the post which had everything they needed to take part in the experiments and get involved in the fun.
## **Halloween fun**
During October Half Term around 177 families joined in with our Halloween activities, which were sent out in the post as a fun creative way to bring families together. The activities consisted of a Craft box, put together by Lexy at Made By Me Craft Parties. It included a Frankenstein monster lantern with googly eyes that glow in the dark. We also worked with Kiddy Cook who sent out a Cookie monster baking mix, which allowed the children to create their own unique cookie monsters with candy eyes, and blue icing.
Charlotte, Mum of Isla told us:
I would just like to say thank you so much for the Cookie Monster package. With a rubbish rainy day today, we thought it was a perfect day to make the Cookie Monster biscuits. My 1 year old daughter Isla got diagnosed with infant acute lymphoblastic leukaemia 16 weeks ago when she was 10 months. Her 6-year-old brother Cody was so chuffed to make these for her and it was a great way of involving him. He tried so hard. Thank you so much we had great fun.
12
## **RAISING AWARENESS OF CHILDHOOD CANCER DURING THE COVID-19 PANDEMIC**
Our aim is to make society aware of the impact that cancer can have on young lives. By bringing the reality of being diagnosed and treated for cancer to the attention of the general public, we will make a change. It is only through continuing to invest in life-saving research that we will effect a change in incidence and survival rates for children and young people. We raise awareness during our campaigns to stand together against childhood cancer and bring hope to young patients and their families.
To raise awareness of cancer occurring in children and young people we ran multiple campaigns, including World Cancer Day, Brain Tumour Awareness Month and Childhood Cancer Awareness Month. Through our campaigns we have reached millions of individuals across the UK and internationally.
## **Making our voice heard**
- Over 600 online articles
- Running TV and radio campaigns throughout the year
- Over 130 mentions in printed media
- Grown our social media audience
## **Childhood Cancer Awareness Month**
One of the key moments in our year is Childhood Cancer Awareness Month which takes place in September. Symbolised by the colour gold and a gold ribbon, we come together with a number of other cancer charities internationally to help raise the profile of childhood cancer. For Children with Cancer UK this means that gold is splashed across all of our communications and we sold a gold ribbon to our supporters. We reached thousands of people on social media and engaged with hundreds of thousands of our existing supporters during this campaign.
With special thanks to Bella-Rose, Sophia, Harry, Suki, Darren, Christopher and Maisie who all shared their stories during our campaign in 2021. You are all so inspiring and we thank you for sharing your experience so generously with us, our supporters and the general public.
## **Telling the story of childhood cancer**
We are so grateful to all the families affected by a childhood cancer diagnosis who choose to share their story. It’s such an important element of how we are able to raise awareness of the realities of being diagnosed and treated for childhood cancer. It also helps us to demonstrate the issues that need addressing and are so generously funded through our supporters.
Thank you to the 8 new families who told their story in 2021 and welcome to the Children with Cancer UK family: Alfie, Finley, Bridenni, Lauren, Chloe, Christopher, Frankie S and Harry E
13
## **FUNDRAISING HIGHLIGHTS**
Our greatest fundraising achievements in 2021, that have helped more children with cancer ring the end of treatment bell, include:
- We saw 331 participants take on a Rat Race event, raising over £140,000
- 174 supporters took up a non-running challenge in the UK or overseas and raised over £104,000
- We launched our very first Virtual Gold Ribbon Run in September during Childhood Cancer Awareness Month, where people could choose to run, walk or jog 25km, 50km or 100km within the month.
- Steve Lodge organised 80 people to climb Mount Snowdon and raised over £25,000 (Steve also took on the London Marathon for us!)
- Sophy Gurl raised over £11,000 for Children with Cancer UK in March when she did a sponsored head shave to support her niece, Grace, who is currently having cancer treatment
## **London Marathon Events 2021**
The 2021 Virgin Money London Marathon took place on Sunday 3[rd] October and was our first major event back following the pandemic.
As restrictions continued to change throughout the year, we saw the team numbers increase and decrease leading up to the day of the event but on race day we had a team of just under 900 runners take to the streets and complete 26.2 miles through London, along with almost 36,000 other runners. It was a hugely successful day and we were delighted to be able to be out cheering our team on as they went on to cross the iconic finish line on the Mall.
In 2021 our team raised over £2million from the Virgin Money London Marathon from the in person and virtual Virgin Money London Marathon, which was incredible and higher than expected. 2021 was also the final year of Virgin Money sponsoring the London Marathon. The new sponsor for 2022 is TCS.
## **Children with Cancer UK Swim Serpentine**
2021 was the final year of the partnership with London Marathon Events. The event had been cancelled in 2020 due to the pandemic. The launch of the event came later than expected in June 2021 so time to recruit was restricted. By event day on Saturday 18[th] September, we had an impressive team of 304 take to the water.
The 2021 Swim Serpentine team raised over £93,000.
## **The Great North Run**
The 2021 Great North Run saw an adjustment to the usual route for 2021 due to the pandemic allowing for more social distancing. This didn’t stop our team of over 230 runners taking to the street of Newcastle upon Tyne and completing the 13.1 mile course, getting the opportunity to cross the Tyne Bridge twice!
14
Our team raised an amazing £77,000 in 2021.
## **Individual Giving**
- Our TV ads reached over 152 million people in 2021, with 59,052 people responding to our text to donate ask. A further 5,961 of these signed up to give a regular gift. The year 1 income from the one-off and regular gifts is expected to be £439k.
- Across our gaming products (Grand Draw and Lottery), we’ve raised just over £2.3 million with nearly £1.7 million from our Grand Draws.
- £1.6m from gifts in Wills
- Our ‘Remembering’ in memory tribute site raised £33k.
- £2.8 million brought in from cause regular givers from over 55,000 supporters
- Over £1million raised from cash appeals to our existing supporters.
## **Acquisition of committed givers**
We continued to recruit committed regular givers in 2021 via our TV advertising and other digital campaigns, taking our total number of active cause regular givers at the end of the year to over 50,000. The Christmas TV advert in particular performed exceptionally, and we received nearly double the expected number of responses to the TV adverts (24k compared to forecast of 12k).
## **Retention, Stewardship, and legacies**
Stewardship of our supporters and potential legacies remained a priority in 2021 and our bi-annual newsletter, ‘The Chime’, saw significant engagement and donations from a soft ask. This provides promising indications of our supporters’ ongoing engagement with our work. We will be continuing to look at embedding stewardship within all of our supporter journeys, to ensure they feel valued and continue to give.
## **Digital campaigns**
Optimising digital channels has increased income across the programme in 2021. We’ve continued to develop and test our microsites, including gaming microsites, ‘Remembering’ in memory tribute site and our main donation platform. Email marketing also remains an important income stream and messaging aligns with our cash programme to ensure income is maximised. We also continued to recruit new regular givers through digital, including paid social donation & lead gen campaigns.
15
## **FUNDRAISING COMPLIANCE**
Children with Cancer UK values the privacy of all those who support us in our work; we have systems in place to ensure that supporter data is collected, managed and processed in line with all necessary legislation. We are members of the Fundraising Regulator, which has responsibility for regulating fundraising, sets out the Code of Fundraising Practice and investigates and takes appropriate action on cases of public concern. Children with Cancer UK adheres to the Code of Fundraising Practice set by the Fundraising Regulator and also fully complies with the Fundraising Preference Service. We comply with charity law, fundraising law and the data protection regulations. We monitor our fundraisers, volunteers and any third parties that work for us to ensure that they adhere to our high standards.
We will ask the donor how they want to hear from us about our work and appeals. If the donor wants to stop hearing from us they can, email, phone, write or click on the link in our emails. We will always take action, so they can feel confident in contacting us at any time.
We will keep the donor’s personal information secure and will only use it to communicate with the donor; to process orders and donations; to keep the donor informed; for analysis and to improve our activities. We will NOT share the donor’s details with other charities or sell it to businesses. Some organisations help us with our fundraising, but will only use the donor’s data under our instruction and only when fully compliant with how we process personal data as set out in our Privacy Policy (Reviewed February 2022).
Children with Cancer UK continues to adhere to and review policies relating to GDPR and work alongside an external consultant, Protecture, to ensure that we are fully compliant.
Children with Cancer UK works with some professional fundraising agencies to assist with certain elements of our fundraising, by telephone and SMS channels. We have robust contracts in place with these agencies, specifying that staff carrying out these activities should be trained and adhere to all applicable laws, regulations and codes, such as the Code of Fundraising Practice and the Data Protection Regulations. We also expect these organisations to reflect our values when talking to supporters and to voluntarily subscribe to the Fundraising Regulator.
To ensure the agencies we engage are operating to the required standards and that people should never feel harassed or pressurised to give, we carry out appropriate monitoring which includes: call monitoring, site visits and live call listening and mystery shopping. We attend training sessions of their staff and give training to staff in respect of each fundraising campaign. We require all our staff and the agencies we deal with to comply with our Vulnerable People Policy, which provides guidance on how to identify a potentially vulnerable person and actions to take to considerately disengage from the fundraising process.
Children with Cancer UK require its staff and any agencies contacting our donors and members of the public on our behalf to comply with the Data Protection Law and guidelines provided by the Fundraising Regulator and Institute of Fundraising. Children with Cancer UK take all reasonable care to protect vulnerable adults in accordance with the Institute of Fundraising guidance set out in their document ‘Treating Donors Fairly: Responding to the needs of People in Vulnerable Circumstances and Helping Donors make informed Decisions.’
We adhere to the Fundraising Regulator Promise ensuring that our fundraising is legal, open, honest and respectful. We truly value our supporters, which is why, in 2018, we published our Supporter Charter as a commitment to our supporters.
16
Our Feedback and Complaints policy was reviewed in February 2020 and we will continue to review this regularly. Complaints are investigated thoroughly and corrective action taken as appropriate. During our financial year (Jan – Dec) 2021 we received 125 complaints (source Raiser’s Edge) across all teams which is a significant drop on the previous year (248 complaints, source Raiser’s Edge). Like last year we still have a large number of complaints regarding clothing collections, however we have worked hard with the supplier to change some elements of the collection to make it better for supporters and I believe this is reflected in the drop in complaints.
We continue to closely monitor all of our fundraising activities and will always strive to ensure they are of the highest standard and reflect the wishes and preferences of all our generous supporters. There may be occasions when we have not met these high standards and we will work hard to learn from our mistakes and to make sure they don’t happen again. If our supporters and members of the public are unhappy with any aspect of our work we encourage them to give feedback, and take any comment or complaint seriously. We use this valuable feedback to help shape our future fundraising campaigns and improve our overall service and commitment to our supporters.
We are here to talk and listen to you – we welcome and actively encourage feedback and make it clear how people can get in touch with us.
A member of the Fundraising Regulator, the independent regulator of fundraising in the UK, Children with Cancer UK is committed to best practice in fundraising and follows the Regulators Fundraising Promise and Code of Fundraising Practice laid down by the regulator.
We still have a mixture of both office and home working in **Supporter Care** due to the ongoing restrictions with COVID-19. However we are now hybrid working with the team splitting the week between home and office working. This continues to work well for us and the technology we have installed continues to work well. Looking ahead to the new **Salesforce database** we are already exploring how we can streamline our current processes.
17
## **THANK YOU**
A massive thank you to all our supporters and fundraisers, who despite the pandemic, helped us raise an incredible £14.8m in such a difficult year.
To our corporate partners:
- Ladbrokes
- Kwik Fit
- Lockton
- Amazon
- Unilever – Zendium
- BGC Partners
- Ling Designs
- Tesco
- UHY Hacker Young
- Give a Car
- Office Beaver
- Rye Bay Capital
- Paperchase
To our dedicated Trustees:
- David Gibbs – Chair
- Virna Midgley
- Alex Leitch – Deputy Chair
- Caroline Randerson
- Phil Hall
All our supporters and volunteers who have helped improve the lives of children with cancer and their families – thank you.
A very special thank you goes to all the extraordinary families who have shared their experiences in 2021. Your involvement is central to our work and your help in raising awareness and vital funds to help young cancer patients is invaluable.
18
## **FINANCIAL REVIEW**
Incorporating the Directors’ Strategic Report and Administrative Report for Companies Act Purposes
Registered Charity Number: 298405 Inaugurated by Diana, Princess of Wales Company limited by guarantee, Number: 4960054
19
The Trustees of Children with Cancer UK present their Annual Report for the year-ended 31[st] December 2021 under the Charities Act 2011 and the Companies Act 2006, including the Directors’ Report and the Strategic Report under the 2006 Act, together with the audited financial statements for the year.
## **Financial review**
The Consolidated Statement of Financial Activities (SOFA) set out on page 38, shows the financial results for Children with Cancer UK and its trading subsidiary: Helping Children with Cancer Limited.
Our total income has increased this year from £13.7 million to £14.8 million. Although we continue to feel the longer term impact of the COVID-19 pandemic on our fundraising operations, the increase of over £1 million in our income can be attributed to a recovery in our sporting events. The London Marathon has historically been an important fundraising event for us with a large presence of runners raising a significant amount of sponsorship income. The return of this live event during the end of 2021 helped increase the income from our Sporting events from £1.7 million to £2.7 million. We also observed a slight recovery from our Community fundraisers with 20% growth. We plan to build on this growth area for 2022.
Our income from Corporate and philanthropy continued to struggle during 2021 with no growth from 2020 activity. These income streams continued to be impacted with organisations not being able to run face to face fundraising events and the financial disruption faced by our corporate supporters due to COVID-19. We anticipate this to be an important development area during 2022 to create a sustained pipeline for future years.
However, our continued investment in online and mainstream media has, in addition to broadening the awareness of our cause, led to sustainable growth in individual giving and regular giving. Both of these areas have seen growth during the year and provide core income streams with which we can engage with our supporters. This year the number of regular givers we have, through various channels, has reduced slightly from 55,000 to 52,000. This has been as a result of a review and analysis on the acquisition program during 2021.
Our individual giving income stream has achieved income of £5 million this year, which is a similar level as last year. This reflects the tough fundraising environment of our appeals programme, raffles and acquisition campaigns. Last year our legacy income at £2.1 million was the highest in the charity’s history. This year we have maintained this level with £2 million income.
The continued impact of the pandemic, and the effect on our income streams and risk profile, has meant that we have carefully considered our cost base and completed various cost saving initiatives. We were therefore able to manage our expenditure down from £15.3 million to £9.9 million.
The COVID-19 pandemic had a significant impact on research in the UK and resulted in delays for many existing research projects. As a result of the COVID-19 pandemic we were limited in our efforts to fund new projects and as a result our total grant awards decreased from £7.4 million to just over £2 million.
20
We ended the year with a surplus of £5.2 million increasing our total reserves to £14.5 million. The increase in reserves will be used to fund the current years charitable spend.
For every £1 donated, we spend 80p on fighting childhood cancer.
- 30p on research projects
- 29p on welfare projects
- 21p on raising awareness
We reinvest 20p from every £1 raised, to raise even more money.
## **For every £1 we spend on fundraising, we raise £6 more.**
## **Reserves**
At the end of the year, the charity held £14,455,222 (2020: £9,295,761) in total reserves. All funds were held in unrestricted reserves.
The restricted funds raised comprise of donations that were to be spent on specific causes and projects as detailed in Note 19.
Unrestricted reserves are generated when the supporter does not stipulate how the income may be spent. They are therefore available to be applied at the discretion of Trustees to any of the charity’s charitable purposes.
The Trustees are aware of their role as custodians of these funds and plan to disburse the funds in a structured and cautious manner to meet the long term objectives of the charity
The Trustees consider the reserves to have a dual role; to provide a buffer to allow operating expenditure to be carefully minimised should the need arise, as well as facilitate the following year’s grant award programme. The remainder, is set aside for fluctuations in income that could impact the charity’s ability to carry out its services.
Therefore, £7m has been set aside from total reserves to fund the current year’s charitable spend of £7m, with a further £1m set aside to invest in to a digital transformation project to help secure existing and future fundraising potential. This leaves approximately £6m as a reserve for operational expenditure.
Although a £6m buffer is a slight increase from the previous financial year this will enable the charity to operate without any income for approximately 5 months. This is below the free reserves target of 6 months but deemed to be acceptable by Trustees in the current climate.
The Trustees intend to review the policy again in 2023 after the full impact of COVID-19 and current identified risks becomes clearer.
21
## **STRATEGIC PLANS 2022 AND BEYOND**
The charity, set up by The O’Gorman family, has been doing outstanding work for over thirty years leading the way in childhood cancer research and supporting children, young people and their families when they are at their most vulnerable.
The pandemic has had a huge effect on fundraising for all charities, with many major events having been cancelled, but Children with Cancer UK is proud to have continued its commitment to support research projects throughout this difficult period. We have put recovery plans in action and we are delighted that we are facing increased engagement from donors including corporates and individual givers.
Our vision remains a world where every child survives cancer and the team will continue to strive towards that with the following goals:
- Deliver an increased programme of research spend to drive real change in paediatric cancer diagnosis, treatment and understanding
- Develop our understanding of gaps in funding of wellbeing and support services offered to families who have experienced childhood cancer
- Increase the number of donations to ensure that there is continued funding of vital research and wellbeing projects
- Create impactful campaigns to drive awareness in the wider community about the reality of being a child or young person with cancer and highlight the need for mental health support for them and their families
- Revitalise our communications with a rebranding strategy that reinforces our message of support for children and young people with cancer and their families
- Work with local, national, trade and consumer media to amplify the voice of the charity to highlight the incredible projects that our researchers have overseen and to offer insights into future developments
- Enlist more Ambassadors, including business, celebrity, patient and families to highlight the significance of the charity and recruit a new generation of supporters
- Continue to collaborate with like-minded charities, universities and organisations to support their work and to use our combined resources to drive life-changing projects
- Develop a fundraising initiative that becomes a major calendar event for Children with Cancer UK and its supporters
- The continued success of the charity is due to the passion and tenacity of all those involved from donors and fundraisers to volunteers and dedicated team members.
Children with Cancer UK’s funds, thanks to the generosity of our donors, will continue to bring together some of the world’s greatest scientific minds including the next wave of clinician scientists and research leaders. Our support will encourage their long-term career progression through a number of dedicated programmes, all of which will take us ever closer to the charity’s aim of living in a world where every single child and young person survives cancer.
22
We would like to thank all our supporters for your continued investment. It is loyal supporters that will ensure that together we are able to continue to build on this charity's wonderful legacy, delivering even greater impact, for many years to come.
## **Going Concern**
The Financial Statements are approved during a period of recovery from COVID-19, but also a period of new uncertainties including the current cost of living crisis. The Charity is constantly assessing the short and long term impact on its fundraising activities in the current climate.
Along with the Finance and Operations Committee, The Trustees have reviewed the proposed budgets and cash flow to December 2023 and have scrutinised the reserve position, including cash held in the bank and investments. During this review the Trustees priority was to ensure the Charity is able to endure any decline in income or unexpected increase in costs.
The Reserves policy is reviewed regularly and it is vital to ensure the charity holds sufficient reserves to fund not only its ongoing grant award programme, as well as to ensure the charity can cover its operational commitments. Any risks identified are considered during each review. The Trustees have also drawn upon the experience and lessons learned during the COVID-19 pandemic, where expenditure was only being committed if it can be covered either through our fundraising activities or the reserves.
The Finance and Operations Committee monitor the financial position of the charity on a monthly basis. As well as monitoring the current financial position of the charity, the committee also review the ongoing budget, reporting any variances and ensuring the cash flow and investments are in line with projections. The committee report to the Trustees and highlight anything that needs their attention at the subsequent Trustee meeting.
Each budget that was presented had considered various scenarios, including a drop in income and/or unexpected increased in expenditure. The most likely scenario was presented to the Trustees. These scenarios are closely monitored and constantly reviewed so any scenario can be updated and incorporated in to any reforecast which is performed at least quarterly. This approach enables the charity to respond promptly and effectively to any change of environments.
In their assessment of going concern the Trustees have considered not only the impact on the charity as a result of the COVID-19, but also any new identified risks, including the increase in energy prices and the cost of living crisis. This is an area that will be closely observed, but the current impact to our fundraising is low.
With the return of in person fundraising with events like the London Marathon and the Ball, the Trustees are confident that our fundraising activities can return and in the case of the Ball exceed pre COVID-19 levels in 2023. At the time of writing indications are that it is possible to have a return to pre COVID-19 by the end of 2023. The Trustees will continue to monitor the situation and are aware that if any situation develops that threaten this view then this opinion may change.
23
The Trustees are confident that there are currently significant cash balances should additional liquidity be required to meet the liabilities as they fall due and Children with Cancer UK have appropriate reserves and could adapt to future funding changes. Appropriate consideration of risks as part of its normal risk management processes and mitigating actions both already taken and available to be taken.
The trustees believe that although there is uncertainty identified the charity remains in a strong position to use its cash deposits to take advantage of any opportunities and they are at a sufficient level to ensure the Charity will continue as a going concern for the foreseeable future, being at least 12 months from the date of approval of the financial statements. Accordingly the Trustees consider it appropriate for the going concern basis to be adopted for these accounts.
## **Investments**
The Memorandum of Association allows the charity to deposit or invest funds in any manner but to invest only after obtaining such advice from a financial expert as the Trustees consider necessary and having regard to the suitability of investments and the need for diversification.
The charity recognises that it must have enough resources to carry out its present and future activities effectively. Therefore, the Trustees have agreed to hold sufficient cash levels, invested mainly in instant access deposits, to meet fluctuating needs.
The charity investment policy is reviewed regularly and states that the longer term funds must produce the best financial return for an acceptable risk. The fund must balance the need to support research grants with the objective for capital growth and inflation protection. The Trustees feel the 2021 performance of the investments met the objectives of the policy and recognise the opportunity to identify higher performing funds for 2022 whilst still within an acceptable risk.
The charity currently holds £10.3m of investments held for the longer term. This comprises £1.9M in an investment portfolio managed by Barclays Investment Managers and £8.3m in cash deposits. The charity also holds £4.6m in short term cash deposits.
The Trustees are keen to ensure that the cash funds are not exposed to any risk since this cash value has already been promised to grant holders. As at 31st December 2021, our grant liabilities are close to £9.1m (2020: £9.9m).
24
## **Risk and internal control**
The Trustees have overall responsibility for ensuring that the Charity has an appropriate system of controls, financial and otherwise. They are also responsible for safeguarding the assets of the Charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities and to provide reassurance that:
- its assets are safeguarded against unauthorised use or disposition;
- proper records are maintained and financial information used within the Charity or for publication is reliable; and
- the Charity complies with relevant laws and regulations.
As part of the Charity’s risk management process the Trustees acknowledge their responsibility for the Charity’s system of internal control and reviewing its effectiveness. It is also recognised by the Trustees that such a system is designed to manage rather than eliminate the risk of failure to achieve the Charity’s objectives and can only provide reasonable, not absolute, reassurance against material misstatement or loss.
## **Principal risks and uncertainties**
At the start of 2020 the COVID-19 Pandemic was not an identified risk. Plans were immediately put in place and a full review of all the strategic risks that had previously been identified during the year in review was undertaken to incorporate this new risk. There was a high level of Trustee engagement throughout this period. Along with the review of the strategic risks that had a particular focus on COVID-19, a separate COVID-19 risk log was developed. This was regularly updated during 2021 to respond to the changing environment.
As with many organisations in the sector COVID-19 has had an impact on multiple areas of the organisation. Whilst the long term impact of the pandemic is still to be seen, several plans have been implemented to mitigate this risk in the short term with longer term plans being developed. These short term strategies continue and include regular management meetings, continuous review of up to date income figures, engagement with all suppliers to review costs, strict expenditure controls with direct Trustee involvement, evaluation and renegotiation of contracts where appropriate, redeployment of resources where necessary and identification, exploitation and investment of any new fundraising opportunities like digital fundraising.
The Charity continues to be heavily reliant on mainstream fundraising income to fund charitable activity, the major risk being faced is that income falls to a level that compromises the Charity’s ability to meaningfully fund future charitable activity – whilst at the same time maintaining reserves at a stable level. This risk continues to be managed by the Charity by diversifying its income streams and investing in new fundraising channels. The Charity is continuing the process of implementing ‘strategic imperatives’ that will guide its future vision and strategy.
25
The seven strategic risks that were identified prior to COVID-19 are listed below.
`o` Fundraising `o` Profile & Brand `o` Regulatory compliance `o` Financial `o` Infrastructure & Operations `o` Governance `o` Charitable Impact
These risks have been reviewed with a renewed focus on the recovery from COVID-19 and new uncertainties including the current cost of living increases. They are assessed in terms of probability and impact with a mitigation strategy put in place if required. This forms part of the charity’s annual risk management strategy.
The principal risk for the trading subsidiary is its reliance on short term and ad hoc commercial arrangements to generate income. We are investing in improving our trading income streams to manage this risk.
The strategic risks have been reviewed by the Trustees. Some of the issues discussed include, continued Governance improvements, energy and other cost of living increases, Post COVID long term strategy and organisational structure. These discussion points intersect with all the strategic risks and will continue to be reviewed regularly by both the Trustees and Senior Management.
## **Structure, governance and management**
The financial statements comply with current statutory requirements, the Memorandum and Articles of Association, Statement of Recommended Practice (SORP FRS 102) and current accounting standards (FRS 102).
The Trustees have considered and acknowledge the principles and recommendations set out in the Charity Governance Code. The Senior Leadership Team were tasked of reviewing the Charity's governance against the Charity Governance Code and identifying key areas for development. It was recommended to the Trustees that an independent Governance Review was initiated. The Trustees instigated this review and tasked the Senior Leadership Team to implement all recommendations. Significant progress has been made with over 90% of the recommendations completed and plans in place for the remaining items to be addressed within the next 12 months.
## **Governing documents**
These financial statements are for Children with Cancer UK and its subsidiary Helping Children with Cancer Limited.
Children with Cancer UK is a company limited by guarantee and operates under its Memorandum and Articles of Association dated 11[th] November 2003 as amended by special or written resolutions, dated 30[th] November 2004, 22[nd] December 2006, 12[th] May 2007, 28[th] July 2016 and 13[th] December 2021.
On 14[th] May 2007 the reporting charity changed its name from CHILDREN with LEUKAEMIA UK to Children with Cancer UK. However, the charity continued to use the working name of CHILDREN with LEUKAEMIA until 11[th] May 2011.
26
The charity operates under its Trust Deed (dated 4[th] January 1988) and Variation of Trust Deed (dated 10[th] December 2003).
## **Aims and Objectives**
## **Purposes and Aims**
The charity’s objects as amended by written resolution of 12[th] May 2007, and 28th July 2016 are shown below:
- i) To promote the relief of children and young people suffering with leukaemia or any other form of cancer (and allied disorders) and of their families;
- ii) To raise public awareness and knowledge in matters relating to leukaemia or any other form of cancer (and allied disorders) affecting children and young people; and
- iii) To promote research into the causes, alleviation, prevention, treatment and cure of leukaemia or any other form of cancer (and allied disorders) affecting children and young people and to publish the useful results of such research.
Our aims are to determine the causes, find the cure and provide care for children with cancer.
We fund life-saving research into the causes, prevention and treatment of childhood cancer.
We fund innovative welfare projects to provide better care for young cancer patients and their families.
We campaign to raise awareness of childhood cancer to protect more children and to improve the lives of young cancer patients, today and for future generations.
We are a member of the Association of Medical Research Charities.
We are also a member of the National Cancer Research Institute.
Further details of the projects we fund are detailed in note 22.
## **Public Benefit**
The Trustees continue to give due regard to the public benefit provided by the charity in relation to its charitable purpose as set out by the objectives above and have given due consideration to the relevant guidance issued by the Charity Commission. The Trustees will continue to ensure that the activities that promote the charitable objects above will be applied to provide public benefit.
## **Board of Trustees**
The governing body of the reporting charity is the Board of Trustees, which has a total of five members (2020: seven). The Trustees of the charity also act as the Directors of the charitable company. The Board meets at least three times a year together with the Chief Executive and other senior management where appropriate.
27
The Finance and Operations Committee and Marketing and Communications Committee are subcommittees of the Board. The subcommittee meet at least bi-monthly and consists of a combination of Trustees, Staff, External Advisors and Specialised Volunteers (if required). The committee will draw to the attention of the Board any urgent issues that require authorisation, disclosure or action and escalate any urgent issues for immediate attention outside of the Board meeting schedule.
## **Trustee appointment and induction**
There were three new appointments (2020: three) to the Trustee Board in 2021 and an additional two post year end. Six Trustees left the board post year end. These were planned resignations including two trustees from our founding family and in line with our succession plan. The selection of Trustees is made based on vacancies arising, sympathy with the objects of the charity and the additional skills and experience that potential new Trustees are able to afford. Under the Articles of Association, Trustees are appointed by a majority vote of the members (who are all the current Trustees) by ordinary resolution.
Each new Trustee receives the Charity Commission publication ‘The Essential Trustee: What you need to know’ as well as the most recent published annual report. The Chief Executive offers an induction day to all Trustees which provides full information about the operations of the charity.
## **Management**
The Trustees exercise executive responsibility for the governance of the charity and, through the Chairman, supervise the management of the charity by the Chief Executive and the senior management team. The Chairman and Chief Executive also task the Board with decision-making on strategic management issues as well as overseeing the research grants application process and monitoring the progress of awarded grants.
The senior management carry out the operational running of the charity and the coordinating of fundraising appeals and events.
## **Remuneration**
The salaries of Children with Cancer UK staff are periodically benchmarked against other charities to ensure that salary levels are market competitive and sufficient to attract and retain staff of the appropriate calibre. All staff posts are periodically evaluated to ensure that salary levels are reflective of industry and organisational needs, as well as individual and charity performance. In recruitment of a new post, an assessment is made of the requirements of the role in terms of skills, experience, competency and urgency. The salary is then determined on the basis of this assessment and the current market conditions.
Salary Bands have been set based on external benchmarking, anecdotal data from head-hunters and recruiters, and charity sector salary surveys. The Salary Bands are reviewed at least every two years.
The Charity is compliant with the Hutton Fair Pay Review with the salary of the highest paid employee being no more than four times the median salary of the organisation.
28
## **Trading Subsidiary**
Helping Children with Cancer Limited (company registration 2807553) is the wholly owned trading subsidiary of Children with Cancer UK. Its principal purpose is to raise funds for the charity and all profits are donated under Gift Aid.
The principal activity of the Company is the licensing of the name and logo of the charity for use in corporate sponsorship, commercial agreements and royalties from contribution to clinical trials.
The trading activities generated profit for the year of £60,072 (2020: £11,638) which will be paid to Children with Cancer UK under the Gift Aid Scheme. It is anticipated that the trading activity within the subsidiary will continue at a similar level during the current year.
The trading subsidiary holds assets of £23,740 (2020: £45,069) and liabilities of £23,640 (2020: £44,969) with funds of £100 as at 31st December 2021.
The charity also holds 100% of the share capital of Children with Cancer Research Limited (09442350) which is currently dormant.
## **Related parties**
The Charity has a related party and conflict of interest policy in place which accompanies the declaration of interests submissions completed by all Trustees and senior management. An internal conflict of interest register is in place which is updated when a conflict of interest has been identified and is reviewed at least annually.
29
## **Grant making policy**
It is the Trustees’ policy to maximise the proportion of its charitable output that is achieved through grant making.
## **Welfare grants**
There is no open application process for welfare grants and no welfare grants are given to individuals. The Trustees determine which organisations are to be supported. In 2021, a total of £1,297,488 (2020: £1,285,296) was awarded to welfare projects.
## **Research grants**
The Trustees aim to award an increasing proportion of the charity’s grants to scientific and medical research in child and young person cancer. The charity’s Code of Practice adheres to the standards set by the Association of Medical Research Charities (AMRC).
The charity advertises guidelines and invite applications for project grant rounds. Project applications are subject to formal internal and external peer review followed by scrutiny by our scientific advisor panels (SAPs) before the Trustees determine which projects to support. We also occasionally support research through other AMRC members.
In 2021, a total of £812,027 (2020: £6,167,773) was awarded to research projects. Project funding is directed in two areas of concern:
1. Research into treatment and survival
2. Research into prevention and causes
We also fund some 5-year Post-doctoral Fellowships and Clinical PhD Studentships on these topics at leading research Institutions regarding child and young adult cancer.
30
## **REFERENCE AND ADMINISTRATION**
Children with Cancer UK (previously known as CHILDREN with LEUKAEMIA UK) was set up in memory of Paul O’Gorman who died on 6th February 1987 and his sister Jean, who died on 3rd November 1987. The charity was inaugurated by Diana, Princess of Wales on 12th January 1988 at Mill Hill County High School where Paul had been a pupil.
## **Trustees**
The Trustees of Children with Cancer UK are the charity’s Trustees under charity law and the directors of the charitable company:
## **Current Trustees**
David Gibbs (Chair of Trustees) (Appointed 22[nd] February 2021) Alex Leitch (Deputy Chair) (Appointed 4[th] June 2021) Caroline Randerson Phil Hall (Appointed 13[th] December 2021) Bruce Morland (Appointed 5[th] July 2022) Georgie Wolfinden (Appointed 14[th] November 2022)
## **Previous Trustees**
Virna Midgley (Resigned 3[rd] August 2022) Ann Amaya-Torres (Resigned 12[th] March 2022) Eddie O’Gorman OBE (Founder and previous Chair of Trustees) (resigned 12[th] January 2022) Sandra Mileham (resigned 12[th] January 2022) Linda Robson (resigned 12[th] January 2022) Nick Goulden (resigned 18[th] March 2022)
## **Chief Executive Officer**
Jo Elvin (Appointed 19[th] April 2022) David Gibbs (Honorary) (Appointed 1[st] January 2022) (Resigned 19[th] April 2022)
## **Senior Management**
Gary Murphy (Chief Operating Officer) Hannah Chambers (Head of Marketing and Communications) Emily Roff (Head of Events, Community and Sports) (Maternity Leave) Kerry Russell (Head of Events, Community and Sports) (Maternity Cover) Camelia Vasilcan (Head of Database) Fiona Judge (Head of Supporter Care) Fadil Dugolli (Head of IT)
## **Previous members of the Senior Management during the year were**
Cliff O’Gorman Sarah Goddard
31
**Registered Charity Number** 298405
**Registered Company Number** 4960054
## **Principal office**
51 Great Ormond Street, London WC1N 3JQ
## **Solicitors**
Bates Wells, 10 Queen Street Place, London, EC4R 1BE
## **Auditors**
Crowe U.K. LLP, 55 Ludgate Hill, London, EC4M 7JW
## **Bankers**
National Westminster Bank plc, 30 North Audley Street, London W1A 4UQ
## **Contact details**
Children with Cancer UK 51 Great Ormond Street, London WC1N 3JQ Tel: 020 7404 0808 Email: info@childrenwithcancer.org.uk www.childrenwithcancer.org.uk
## **Scientific Advisory Panel**
We are indebted to the members of our two Scientific Advisory Panels (SAP) who freely give their time and expertise to help drive forward our fight against childhood cancer. Research into childhood cancer is a broad field and we aim to reflect the diversity of the field amongst the membership of our Treatment and Survivorship and our Causes and Prevention Panels. Some members may sit on both panels.
The Chair of the Treatment SAP is Dr Owen Williams, PhD, Reader in Cancer Biology and Head of Cancer Section, UCL Great Ormond Street Institute of Child Health and Great Ormond Street Hospital for Children NHS Trust
The Chair of our Causes and Prevention SAP is Professor Geoff Pilkington, PhD CBiol FRSB FRCPath, Professor of Cellular and Molecular Neuro-Oncology and Head of Brain Tumour Research Centre, University of Portsmouth.
32
## **STATEMENT OF TRUSTEES’ RESPONSIBILITIES**
The Trustees (who are also directors of Children with Cancer UK for the purposes of company law) are responsible for preparing the Strategic Report, the Trustees’ Report and the financial statements in accordance with applicable law and regulations.
Company law requires the Trustees to prepare financial statements for each financial year. Under company law the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charitable company and the group and of the incoming resources and application of resources, including the income and expenditure, of the charitable company and the group for that period. In preparing these financial statements, the Trustees are required to:
- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgments and estimates that are reasonable and prudent;
- state whether applicable UK accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company and group will continue in business.
The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the charitable company’s transactions, disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006 and the provisions of the charity’s constitution. They are also responsible for safeguarding the assets of the charity and the group and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.
Insofar as each of the Trustees of the charitable company at the date of approval of this report is aware there is no relevant audit information (information needed by the charitable company’s auditor in connection with preparing the audit report) of which the charitable company’s auditor is unaware. Each Trustee has taken all of the steps that he/she should have taken as a Trustee in order to make himself/herself aware of any relevant audit information and to establish that the charitable company’s auditor is aware of that information.
This Annual Report of the Trustees, prepared under the Charities Act 2011 and the Companies Act 2006, was approved by the Board of Trustees on 27[th] January 2023 including approving in their capacity as company directors the Strategic Report contained therein, and is signed as authorised on its behalf by:
**David Gibbs Chair of Trustees**
**Date: 27[th] January 2023**
33
## **Independent Auditor’s Report to the Trustees of Children with Cancer UK Opinion**
We have audited the financial statements of Children with Cancer UK (‘the charitable company’) and its subsidiary (‘the group’)] for the year ended 31 December 2021 which comprise the Group Statement of Financial Activities, the Group and Company Balance Sheets, the Group Cash Flow Statement and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).
In our opinion the financial statements:
- give a true and fair view of the state of the group’s and the charitable company’s affairs as at 31 December 2021 and of the group’s incoming resources and application of resources, including its income and expenditure for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act.
## **Basis for opinion**
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor’s responsibilities for the audit of the financial statements section of our report. We are independent of the group in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
## **Conclusions relating to going concern**
In auditing the financial statements, we have concluded that the trustee's use of the going concern basis of accounting in the preparation of the financial statements is appropriate.
Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.
Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.
## **Other information**
The trustees are responsible for the other information contained within the annual report. The other information comprises the information included in the annual report, other than the financial statements and our auditor’s report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.
34
Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.
We have nothing to report in this regard.
## **Opinions on other matters prescribed by the Companies Act 2006**
In our opinion based on the work undertaken in the course of our audit
- the information given in the trustees’ report, which includes the directors’ report and the strategic report prepared for the purposes of company law, for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the strategic report and the directors’ report included within the trustees’ report have been prepared in accordance with applicable legal requirements.
## **Matters on which we are required to report by exception**
In light of the knowledge and understanding of the charitable company and their environment obtained in the course of the audit, we have not identified material misstatements in the strategic report or the directors’ report included within the trustees’ report.
We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:
- the parent company has not kept adequate accounting records; or
- the parent company financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.
## **Responsibilities of trustees**
As explained more fully in the trustees’ responsibilities statement set out on page 33, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.
In preparing the financial statements, the trustees are responsible for assessing the charitable company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.
35
## **Auditor’s responsibilities for the audit of the financial statements**
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.
Details of the extent to which the audit was considered capable of detecting irregularities, including fraud and non-compliance with laws and regulations are set out below.
A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council’s website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor’s report.
## **Extent to which the audit was considered capable of detecting irregularities, including fraud**
Irregularities, including fraud, are instances of non-compliance with laws and regulations. We identified and assessed the risks of material misstatement of the financial statements from irregularities, whether due to fraud or error, and discussed these between our audit team. We then designed and performed audit procedures responsive to those risks, including obtaining audit evidence sufficient and appropriate to provide a basis for our opinion.
We obtained an understanding of the legal and regulatory frameworks within which the charitable company and group operates, focusing on those laws and regulations that have a direct effect on the determination of material amounts and disclosures in the financial statements. The laws and regulations we considered in this context were:
- Companies Act 2006;
- The Charities SORP (FRS 102) 2019; and
- Taxation Legislation
We assessed the required compliance with these laws and regulations as part of our audit procedures on the related financial statement items.
In addition, we considered provisions of other laws and regulations that do not have a direct effect on the financial statements but compliance with which might be necessary to the charitable company’s and the group’s ability to operate or to avoid a material penalty. We also considered the opportunities and incentives that may exist within the charitable company and group for fraud. The laws and regulations we considered in this context for the UK operations were:
- Charity Commission regulations
- General Data Protection Regulation (GDPR)
- Employment legislation
Auditing standards limit the required audit procedures to identify non-compliance with these laws and regulations to enquiry of the Trustees and other management and inspection of regulatory and legal correspondence, if any.
36
We identified the greatest risk of material impact on the financial statements from irregularities, including fraud, to be within the timing of recognition of income and override of controls by management. Our audit procedures to respond to these risks included enquiries of management, and the Board of Trustees about their own identification and assessment of the risks of irregularities, sample testing on the posting of journals, reviewing regulatory correspondence with the Charity Commission, and reading minutes of meetings of those charged with governance.
Owing to the inherent limitations of an audit, there is an unavoidable risk that we may not have detected some material misstatements in the financial statements, even though we have properly planned and performed our audit in accordance with auditing standards. For example, the further removed non-compliance with laws and regulations (irregularities) is from the events and transactions reflected in the financial statements, the less likely the inherently limited procedures required by auditing standards would identify it. In addition, as with any audit, there remained a higher risk of non-detection of irregularities, as these may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal controls. We are not responsible for preventing non-compliance and cannot be expected to detect non-compliance with all laws and regulations.
## **Use of our report**
This report is made solely to the charitable company’s members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company’s members those matters we are required to state to them in an auditor’s report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company’s members as a body, for our audit work, for this report, or for the opinions we have formed.
## **Andrew Thomas**
Senior Statutory Auditor For and on behalf of Crowe U.K. LLP Statutory Auditor London
## **Date:** 30 January 2023
37
## **Consolidated statement of financial activities for the year ended 31 December 2021 (Incorporating an income and expenditure account)**
||**Note**|**Total**
**restricted**
**funds**||**Total**
**unrestricted**
**funds**||**Total**
**2021**||**Total**
**2020**|
|---|---|---|---|---|---|---|---|---|
|||**£**||**£**||**£**||**£**|
|**Income from:**|||||||||
|Donations and legacies|4|443,952||14,344,727||14,788,679||13,583,698|
|Other trading activities|4|-||6,850||6,850||48,994|
|Income from
investments||-||48,672||48,672||129,182|
|Other income||-||248||248||131|
||||||||||
|**Total Income**|19|**443,952**||**14,400,497 **||**14,844,449**||**13,762,005**|
||||||||||
|**Expenditure on:**|||||||||
|Raising funds|6|207,687||1,771,965||1,979,652||2,057,943|
|Charitable activities|6, 8|-||7,875,497||7,875,497||13,284,229|
||||||||||
|**Total Expenditure**|6|**207,687 **||**9,647,462 **||**9,855,149**||**15,342,172**|
||||||||||
|Net change in
investments|12|-||170,161||170,161||(25,491)|
||||||||||
|**Net**
**(expenditure)/income**||**236,265**||**4,923,196**||**5,159,461**||**(1,605,658)**|
||||||||||
|**Transfers between**
**funds**|19|**(236,265)**||**236,265**||**-**||**-**|
||||||||||
|**Net movement in**
**funds**||**-**||**5,159,461**||**5,159,461**||**(1,605,658)**|
||||||||||
|Reconciliation of funds:|||||||||
||||||||||
|**Total funds brought**
**forward**||**-**||**9,295,761**||**9,295,761**||**10,901,419**|
||||||||||
|**Total funds carried**
**forward**|19|**-**||**14,455,222**||**14,455,222**||**9,295,761**|
The comparative figures for each fund are shown in note 3 to the financial statements.
38
## **Balance sheet as at 31 December 2021**
## Company Number: 4960054
|ompany Number: 4960054|||||||
|---|---|---|---|---|---|---|
|||**2021**|||**2020**||
||**Note**|**Group**|**Charity**||**Group**|**Charity**|
|**Fixed assets**||**£**|**£**||**£**|**£**|
|Investments|12|10,293,735|10,293,835||10,133,555|10,133,655|
|||**10,293,735**|**10,293,835**||**10,133,555**|**10,133,655**|
|**Current assets**|||||||
|Debtors and prepayments|14|2,336,386|2,342,599||3,110,245|3,149,113|
|Cash deposits||4,596,702|4,596,702||4,554,746|4,554,746|
|Cash at bank and in hand||7,074,406|7,064,133||2,069,985|2,027,417|
|||**14,007,494 **|**14,003,434 **||**9,734,976**|**9,731,276**|
|**Creditors: amounts falling**
**due withinone year **|||||||
|Grants|15,16|(3,965,171)|(3,965,171)||(1,982,298)|(1,982,298)|
|Other|16|(699,942)|(695,982)||(670,401)|(666,801)|
||||||||
|**Net current assets**|18|**9,342,381 **|**9,342,281 **||**7,082,277**|**7,082,177**|
||||||||
|**Total assets less current**
**liabilities**||**19,636,116**|**19,636,116**||**17,215,832 **|**17,215,832 **|
||||||||
|**Creditors: amounts falling**
**due after more than one year **|||||||
|Grants|15|(5,180,894)|(5,180,894)||(7,920,071)|(7,920,071)|
||||||||
|**Net assets**||**14,455,222**|**14,455,222**||**9,295,761 **|**9,295,761 **|
||||||||
|Represented by:|||||||
|**Unrestricted funds**||**14,455,222**|**14,455,222**||**9,295,761 **|**9,295,761 **|
|**Restricted funds**||**-**|**-**||**-**|**-**|
||18,19|**14,455,222**|**14,455,222**||**9,295,761 **|**9,295,761 **|
The net surplus for the financial year dealt within the financial statements of the parent charitable company was £5,159,461 (2020: net deficit £1,605,658).
The notes on pages 41 to 58 form part of the financial statements.
Approved and authorised for issue on behalf of the Trustees on 27[th] January 2023.
**David Gibbs Trustee**
**Alex Leitch Trustee**
39
## **Consolidated cash flow statement for the year ended 31 December 2021**
||||**2021**|||**2020**|
|---|---|---|---|---|---|---|
||||**£**|||**£**|
|**Cash flows from operating activities: **|||||||
|Net cash provided by operating activities|a)||5,090,738|||(1,190,010)|
||||||||
|**Cash flows from investing activities: **|||||||
|Dividends and interest from investments|||(48,809)|||129,182|
|Net additions/(disposals) in the year|||(5,534)|||(4,939)|
|Net cash provided by investing activities|||(54,343)|||124,243|
||||||||
|**Change in cash and cash equivalents in**
**the reporting period**|||**5,036,395**|||**(1,065,767)**|
|**Cash and cash equivalents at the**
**beginning of the reporting period**|b)||**14,979,972**|||**16,045,739**|
|**Cash and cash equivalents at the end of**
**the reporting period**|b)||**20,016,367**|||**14,979,972**|
||||||||
|**Notes to the Cash flow Statement**|||||||
||||||||
|**a) Reconciliation of net (expenditure) to**
**net cash flow from operating activities**|||**2021**
**£**|||**2020**
**£**|
|Net (expenditure)/income for the reporting
period|||5,159,461|||(1,605,658)|
||||||||
|Adjustments for:|||||||
|Dividends, interest and rents from
investments|||48,809|||(129,321)|
|Investment Manager Fees|||5,534|||4,939|
|Net Change in investments|||(170,161)|||25,491|
|Decrease / (increase) in debtors|||773,859|||1,161,900|
|(Decrease) / increase in creditors|||(726,764)|||(647,361)|
|**Net cash provided by (used in) operating**
**activities**|||**5,090,738**|||**(1,190,010)**|
||||||||
||||||||
|**b) Analysis of cash and cash equivalents**|||**1 January**
**2021**|**Cashflow**||**31 December**
**2021**|
||||**£**|**£**||**£**|
|Cash at bank and in hand|||2,069,985|5,004,421||7,074,406|
|Cash held as short term investments|||4,554,746|41,956||4,596,702|
|Cash held as long term investments|||8,355,241|(9,980)||8,345,261|
||||**14,979,972**|**5,036,397 **||**20,016,369**|
40
## **Notes to the financial statements for the year ended 31 December 2021**
## **1. Charity information**
Children with Cancer UK is limited by guarantee with no share capital (registered number 4960054), which is incorporated in England and Wales and domiciled in the UK. The address of the registered office is 51 Great Ormond Street, London WC1N 3JQ. It is also a registered charity (registered number 298405) and as such is a non-profit making organisation.
## **2. Accounting policies**
## (a) Basis of preparation
The financial statements have been prepared on the historical cost basis of accounting, as modified by the revaluation of investments, and in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102), the Companies Act 2006, the Charities SORP (FRS 102) and the accounting policies set out below.
The charity meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy note(s).
Children with Cancer UK is the ultimate parent company. It has two subsidiaries - Helping Children with Cancer Limited and Children with Cancer Research Limited. Children with Cancer UK owns the whole of the share capital of Helping Children with Cancer Limited, a company registered in England and Wales, number 2807553. It also holds 100% of the share capital of Children with Cancer Research Limited, a company registered in England and Wales, number 09442350 which is currently dormant.
The financial statements of the charity and its active subsidiary company are consolidated, on a line-by-line basis, to produce the Group financial statements. The consolidated entity is referred to as ‘the Group’. No separate Statement of Financial Activities has been prepared for the charity as permitted by Section 408 of the Companies Act 2006. The charity has taken advantage of the exemptions in FRS 102 from the requirements to present a charity only Cash Flow Statement and certain disclosures about the charity’s financial instruments.
- (b) Preparation of the accounts on a going concern basis
In their assessment of going concern the Trustees have considered the impact on the charity as a result of identified risks and the COVID19 virus. Although we saw the return of in person events during the current year this continued to have an impact on certain activities including running events and community based fundraising. The Ball had been cancelled for two years and returned in November 2022 exceeding the income for 2019. These events had previously made up approximately 40% of the charity’s income prior to COVID-19.
With the return of in person fundraising with events like the London Marathon and the Ball, the Trustees are confident that our fundraising activities can return and in the case of the Ball exceed pre COVID-19 levels in 2023. At the time of writing indications are that it is
41
possible to have a return to pre COVID-19 by the end of 2023. The Trustees will continue to monitor the situation and are aware that if any situation develops that threaten this view then this opinion may change.
There are currently significant cash balances should additional liquidity be required through any period of uncertainty to meet the liabilities as they fall due and Children with Cancer UK have appropriate reserves and could adapt to future funding changes by adapting costs.
Accordingly, the Trustees believe the Charity's financial resources are sufficient to ensure the Charity will continue as a going concern for the foreseeable future, being at least 12 months from the date of approval of the financial statements and have therefore prepared the financial statements on the going concern basis.
## (c) Financial Instruments
The charity has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at amortised cost. Financial assets held at amortised cost comprise cash at bank and in hand, short term cash deposits together with the group’s trade and other debtors excluding prepayments. Financial liabilities held at amortised cost comprise the group’s short- and long-term trade and other creditors excluding deferred income and taxation payable. No discounting has been applied to these financial instruments on the basis that the periods over which amounts will be settled are such that any discounting would be immaterial.
Investments, including cash held as part of the investment portfolio are held at fair value at the Balance Sheet date, with gains and losses being recognised within the Statement of Financial Activities. Investments in subsidiary undertakings are held at cost less impairment.
- (d) Critical accounting judgements and key sources of estimation uncertainty
In the application of the charity’s accounting policies, Trustees are required to make judgements, estimates and assumptions about the carrying values of assets and liabilities that are not readily apparent from other sources. The estimates and underlying assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.
The estimates and underlying assumptions are reviewed on an on-going basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects the current and future periods.
The key sources of estimation uncertainty that have a significant effect on the amounts recognised in the financial statements are described in the accounting policies and are summarised below:
Residuary legacies – The charity recognises residuary legacies once probate has been granted which therefore requires an estimation of the amount receivable.
42
## (e) Functional/Presentational currency
The functional currency of the charity and its subsidiary is considered to be in pounds sterling because that is the currency of the primary economic environment in which the charity/group operates. The consolidated financial statements are also presented in pounds sterling.
## (f) Fund accounting
Unrestricted funds comprise accumulated surpluses and deficits on general funds and are available for use at the discretion of the Trustees in furtherance of the general objectives of the charity and have not been designated for other purposes.
Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the charity for particular purposes. The costs of raising and administering such funds are charged against the specific fund.
## (g) Income
Income is recognised when the charity has entitlement to the funds, any performance conditions attached to the item(s) of income have been met, it is probable that the income will be received and the amount can be measured reliably.
Voluntary income in the form of appeals, committed giving, sports events and community fundraising income is recognised in the period of receipt. Income received in advance of an event or lottery is deferred until the criteria for income recognition are met.
For legacies, entitlement is taken as the earlier of the date on which either: the charity is aware that probate has been granted, the estate has been finalised and notification has been made by the executor(s) to the Trust that a distribution will be made, or when a distribution is received from the estate. Receipt of a legacy, in whole or in part, is only considered probable when the amount can be measured reliably and the charity has been notified of the executor’s intention to make a distribution. Where legacies have been notified to the charity, or the charity is aware of the granting of probate, and the criteria for income recognition have not been met, then the legacy is treated as a contingent asset and disclosed if material.
Income arising from corporates and trusts is recognised in the period in which the charity has entitlement to the income.
Income from trading activities is recognised in the period in which the service has been provided or product sold.
Investment income from dividends and interest on funds held on deposit is included when receivable and the amount can be measured reliably by the charity; this is normally upon notification of the interest received or receivable from the Bank.
Government grants are recognised on the performance model, when the Charitable Company has complied with any conditions attaching to the grant and the grant will be
43
received. The grant in connection to the job retention scheme has been recognised in the period to which the underlying furloughed staff costs relate to.
- (h) Expenditure and basis of allocation of costs
Expenditure is recognised once there is a legal or constructive obligation to make a payment to a third party, it is probable that settlement will be required and the amount of the obligation can be measured reliably. All expenditure is accounted for on an accruals basis and the majority is directly attributable to specific activities. Other indirect costs are apportioned to activities in accordance with staff activity and an assessment of where the resources have been applied. Irrecoverable VAT is charged as a cost against the activity for which the expenditure was incurred.
Grants to third parties are included in the SOFA when approved by the Trustees when a constructive obligation exists, notwithstanding that they may be paid in future accounting periods.
Support costs include governance costs which are costs incurred to manage the charity in compliance with constitutional and statutory requirements and the direct expenditure and overhead costs relating to the appeals and fundraising functions. They also include the allocation of costs incurred to support and co-ordinate fundraising activities. These costs are allocated across the categories of charitable activities and the basis of this cost allocation has been explained in note 7 of the financial statements.
Expenditure on raising funds includes expenditure specifically incurred for fundraising purposes. This constitutes a mixture of directly attributable costs and apportionment.
## (i) Tangible fixed assets
Tangible fixed assets costing more than £10,000 are capitalised and included at cost including any incidental costs of acquisition, or, where donated, are included at valuation at the date that ownership is acquired.
## (j) Pension scheme
Permanent employees are entitled to join the Grouped Stakeholder Pension Plan provided by Scottish Widows. During 2021, the charity made a contribution of 9% of salary per month to any personal or stakeholder pension scheme selected by all employees serving for more than three months who elected to take advantage of this benefit. The amount charged to the statement of financial activities in respect of pension costs is the contribution payable during the year.
44
## (k) Investments
Investments are a form of basic financial instrument and are initially recognised at their transaction value and subsequently measured at their fair value as at the balance sheet date using the closing quoted market price. The statement of financial activities includes the net gains and losses arising on revaluation and disposals throughout the year.
All gains and losses are taken to the Statement of Financial Activities as they arise. Realised gains and losses on investments are calculated as the difference between sales proceeds and their opening carrying value or their purchase value if acquired subsequent to the first day of the financial year. Unrealised gains and losses are calculated as the difference between the fair value at the year end and their carrying value. Realised and unrealised investment gains and losses are combined in the Statement of Financial Activities.
## (l) Gifts in Kind
Gifts in kind and donated goods and services are recognised in the accounts when the benefit to the charity is reasonably quantifiable and measurable. The value is the price the charity estimates it would pay should it purchase equivalent goods or services.
The estimated valuation of gifts in kind is based on the value of the contribution to the charity, or the valuation the charity would have had to pay to acquire the goods or services. A corresponding amount is recognised within expenditure in the period of receipt.
## (m)Private Medical Insurance
Since October 2017, permanent employees are entitled to join the Group Private Medical Insurance Scheme provided by Bupa. In 2021, the charity paid a premium based on the employee’s ages per month to all employees after serving for more than three months who elected to take advantage of this benefit. The amount charged to the statement of financial activities in respect of private medical insurance is the contribution payable during the year.
45
## **3. Consolidated statement of financial activities for the year ended 31 December 2020**
||**Total**
**restricted**
**funds**
**£**|**Total**
**unrestricted**
**funds**
**£**|**Total**
**2020**
**£**|
|---|---|---|---|
|**Income from:**||||
|Donations andlegacies|274,867|13,308,831|13,583,698|
|Othertrading activities|-|48,994|48,994|
|Incomefrom investments|-|129,182|129,182|
|Other income|-|131|131|
|||||
|**Total Income**|**274,867**|**13,487,138**|**13,762,005**|
|||||
|**Expenditure on:**||||
|Raisingfunds|-|2,057,943|2,057,943|
|Charitable activities|754,531|12,529,698|13,284,229|
|||||
|**Total Expenditure**|**754,531**|**14,587,641**|**15,342,172**|
|||||
|Net changein investments|-|(25,491)|(25,491)|
|||||
|**Net(expenditure)/income**|**(479,664)**|**(1,125,994)**|**(1,605,658)**|
|||||
|**Transfers between funds**|**(47,680)**|**47,680**|**-**|
|||||
|**Net movement in funds**|**(527,344)**|**(1,078,313)**|**(1,605,658)**|
|||||
|Reconciliationof funds:||||
|||||
|**Total funds brought forward**|**527,344**|**10,374,075**|**10,901,419**|
|||||
|**Total funds carried forward**|**-**|**9,295,761**|**9,295,761**|
## **4. Income**
||**2021**
**£**|**2020**
**£**|
|---|---|---|
|**Donations and legacies**|||
||||
|Appeals and associated donations (See below)|4,951,894|4,924,928|
|Committed giving|3,114,654|2,632,190|
|Communityfundraising|1,031,920|1,321,743|
|Corporate and trust donations|953,555|891,830|
|Legacies (see contingent asset below)|1,976,328|2,074,903|
|Sports events|2,760,328|1,738,104|
||**14,788,679**|**13,583,698**|
||||
|**Other trading activities**|||
||||
|Events|6,850|48,994|
||————|————|
||**6,850**|**48,994**|
||————|————|
Included in Donations and legacies in 2021 is a government grant in the form of the Job Retention Scheme for £60,161 (2020 £29,750).
46
## **Contingent asset – legacy income**
As at 31 December 2021, the charity had been notified of a further 33 residuary and pecuniary legacies which have not been recognised as income in the Statement of Financial Activities as they do not meet the criteria as detailed in the accounting policies. These legacies have an estimated value of £1,264,383 which has not been accrued.
## **5. Lottery income**
As part of the charity’s Gambling Commission License (Non Remote License - 000-004700-N306402-010) (Remote License – 000-004700-R-308531-010), during the year the charity has operated three lotteries, a weekly lottery and charity scratch card.
The following ticket sales were received for each lottery where the draw was held in 2021:
||**Ticket sales**
**£**|
|---|---|
|WeeklyLottery|574,957|
|ChristmasRaffle (draw 15th January2021)|561,989|
|SpringRaffle (draw 4th June2021)|419,104|
|Summer Raffle (draw3rd September 2021)|383,457|
|Total|1,939,507|
The Christmas Raffle spans two accounting periods. Although the draw took place during the current accounting period, the closing date was 24[th] December 2020 and all ticket sales were received in the previous accounting period. All other ticket sales were received during 2021 only. All ticket sales have been included within the total income for 2021 and 2020.
In line with the requirements under Social responsibility code provision 4.3.1 of the License Conditions and Codes of Practice of the Gambling Act 2005 the following section details the percentage of lottery proceeds returned to the purposes of the society (Children with Cancer UK) from the lotteries promoted in 2021.
|
otteries promoted in 2021.|||
|---|---|---|
|**Lottery type**|**Lottery Name**|**Percentage proceeds**
**returned to Charity %**|
|Managed directly by Children WithCancerUK|WeeklyLottery|63%|
|Managed directly by Children WithCancerUK|Children withCancerGrandDraw|68%|
|**Total**||**66%**|
47
## **6. Total expenditure**
||**Staff Costs**
**£**|**Direct Costs**
**£**|**Support and**
**Governance**
**£**|**2021 Total**
**£**|**2020 Total**
**£**|
|---|---|---|---|---|---|
|**Expenditure on Raising**
**funds**||||||
|Fundraising Costs|443,087|1,274,561|262,004|**1,979,652**|**2,057,943**|
|||||||
|**Expenditure on Charitable**
**activities**||||||
|Research into Prevention &
Causes|230,745|743,119|99,402|**1,073,266**|**2,751,566**|
|Research intoTreatment|224,819|1,513,823|96,800|**1,835,442**|**5,276,839**|
|Welfare|314,193|2,479,418|138,206|**2,931,817**|**2,712,907**|
|RaisingAwareness|509,480|1,295,395|230,097|**2,034,972**|**2,542,917**|
||—————|—————|—————|—————|—————|
||1,279,237|6,031,755|564,505|**7,875,497**|**13,284,229**|
|||||||
||—————|—————|—————|—————|—————|
||**1,722,324**|**7,306,316**|**826,509**|**9,855,149**|**15,342,172**|
||=========|=========|=========|=========|=========|
||**Staff Costs**
**£**|**Direct Costs**
**£**|**Support and**
**Governance**
**£**|**2020 Total**
**£**|
|---|---|---|---|---|
|**Expenditure on Raising**
**funds**|||||
|Fundraising Costs|718,582|1,006,665|332,696|**2,057,943**|
||||||
|**Expenditure on Charitable**
**activities**|||||
|Research into Prevention &
Causes|310,332|2,329,940|111,294|**2,751,566**|
|Research intoTreatment|323,541|4,843,792|109,506|**5,276,839**|
|Welfare|394,214|2,162,572|156,121|**2,712,907**|
|RaisingAwareness|803,778|1,421,488|317,651|**2,542,917**|
||—————|—————|—————|—————|
||1,831,865|10,757,792|694,572|**13,284,229**|
||||||
||—————|—————|—————|—————|
||**2,550,447**|**11,764,457**|**1,027,268**|**15,342,172**|
||=========|=========|=========|=========|
48
## **7. Support costs**
Support costs are split as follows:
||**Office**
**Administration**
**£**|**Operational**
**Management**
**£**|**Finance /**
**IT / HR**
**£**|**Communications**
**and Marketing**
**£**|**Governance**
**£**|**2021 Total**
**£**|
|---|---|---|---|---|---|---|
|**Expenditure on**
**Raising funds**|||||||
|Fundraising Costs|39,718|58,629|110,385|39,847|13,425|**262,004**|
||||||||
|**Expenditure on**
**Charitable**
**activities**|||||||
|Research into
Prevention &
Causes|17,461|9,992|48,529|17,518|5,902|**99,402**|
|Research into
Treatment|17,004|9,731|47,259|17,059|5,747|**96,800**|
|Welfare|24,278|13,893|67,472|24,357|8,206|**138,206**|
|RaisingAwareness|40,419|23,130|112,335|40,551|13,662|**230,097**|
||—————|—————|————|—————|—————|————|
||99,162|56,746|275,595|99,485|33,517|**564,505**|
||—————|—————|————|—————|—————|————|
||**138,880**|**115,375**|**385,980**|**139,332**|**46,942**|**826,509**|
||=========|=========|========|=========|=========|========|
||**Office**
**Administration**
**£**|**Operational**
**Management**
**£**|**Finance /**
**IT / HR**
**£**|**Communications**
**and Marketing**
**£**|**Governance**
**£**|**2020 Total**
**£**|
|---|---|---|---|---|---|---|
|**Expenditure on**
**Raising funds**|||||||
|Fundraising Costs|45,952|89,976|119,230|57,693|19,845|**332,696**|
||||||||
|**Expenditure on**
**Charitable**
**activities**|||||||
|Research into
Prevention &
Causes|17,139|20,766|44,470|21,518|7,401|**111,294**|
|Research into
Treatment|16,864|20,432|43,755|21,172|7,283|**109,506**|
|Welfare|24,042|29,130|62,382|30,185|10,383|**156,122**|
|RaisingAwareness|48,918|59,267|126,923|61,416|21,125|**317,649**|
||—————|—————|————|—————|—————|————|
||106,963|129,595|277,530|134,291|46,192|**694,571**|
||—————|—————|————|—————|—————|————|
||**152,915**|**219,571**|**396,760**|**191,984**|**66,037**|**1,027,267**|
||=========|=========|========|=========|=========|========|
Indirect, support and governance costs are allocated on a per person basis to staff in the office. The time spent by each staff member on every activity of the charity is allocated on a month by month basis throughout the year. Support and staff costs are then allocated to the various charitable activities based on this staff time basis.
49
## **8. Costs of charitable activities**
||**Activities**
**undertaken**
**directly**
**£**|**Grant**
**funding of**
**activities**
**£**|**Support and**
**governance**
**costs**
**£**|**2021 Total**
**£**|**2020 Total**
**£**|
|---|---|---|---|---|---|
|||||||
|Research intoPrevention& Causes|978,291|(4,427)|99,402|1,073,266|2,751,565|
|Research intoTreatment|925,322|813,320|96,800|1,835,442|5,276,839|
|Welfare|1,372,123|1,421,488|138,206|2,931,817|2,712,907|
|RaisingAwareness|1,792,940|11,935|230,097|2,034,972|2,542,917|
||———|———|———|———|———|
||**5,068,676**|**2,242,316**|**564,505**|**7,875,497**|**13,284,228**|
||=========|=========|=========|=========|=========|
## **9. Auditor Costs**
||**Statutory**
**Audit Fee**
**£**|**Other**
**Financial**
**Services**
**£**|**2021 Total**
**£**|
|---|---|---|---|
|||||
|Children withCancerUK|32,300|13,000|**45,300**|
|Helping Children withCancer Ltd|3,600|-|**3,600**|
||———|———|———|
||35,900|13,000|**48,900**|
||=========|=========|=========|
||**Statutory**
**Audit Fee**
**£**|**2020 Total**
**£**|
|---|---|---|
||||
|Children withCancerUK|33,300|**33,300**|
|Helping Children withCancer Ltd|3,600|**3,600**|
||———|———|
||36,900|**36,900**|
||=========|=========|
Other Financial Services excludes £2,600 of irrecoverable VAT.
## **10. Staff costs**
|**10. Staff costs**|||
|---|---|---|
||**2021**
**£**|**2020**
**£**|
|Salaries andwages|1,410,872|2,136,936|
|National Insurance|151,437|224,044|
|Pension|140,623|175,283|
|PrivateMedical Insurance|19,392|14,185|
||—————|—————|
||**1,722,324**|**2,550,448**|
||========|========|
During 2021, the following employees were paid in the following salary ranges.
|**Salary Range**|**2021**
**£**|**2020**
**£**|
|---|---|---|
|£130,000-£140,000|0|1|
|£90,000-£100,000|1|1|
|£70,000-£80,000|0|1|
|£60,000-£70,000|1|3|
There have been 8 (2020: 7) positions that have formed part of the senior leadership team during 2021. The total remuneration including pension contributions for these employees amounts to £501,460 (2020: £715,587).
50
During the year there were six (2020: six) redundancy, termination or settlement payments made totalling £25,852 (2020: £51,488)
An employee that is connected to a Trustee was paid £93,750 gross salary and £8,438 pension contributions (2020: nil gross salary and nil pension contributions). There is no interdependence between the Trustee and the connected person.
The average weekly number of contracted employees during the year was as follows:
||**2021**|**2020**|
|---|---|---|
||**No.**|**No.**|
|CharitableActivities|5|7|
|RaisingFunds|27|38|
|Support, Governance, Operations andAdministration|8|10|
||_______|_______|
||**40**|**55**|
||=======|=======|
## **11. Results of the parent charity**
||**2021**
**£**|**2020**
**£**|
|---|---|---|
|Total income|14,840,817|13,783,863|
||||
|Totalexpenditure|(9,851,516)|(15,364,030)|
||||
|Unrealised gains / (Loses)|170,161|(25,491)|
||—————|—————|
|Net (expenditure) /Income|**5,159,462**|**(1,605,658)**|
||=========|=========|
## **12. Investments**
|**2. Investments**|||
|---|---|---|
||**2021**
**£**|**2020**
**£**|
|Listedinvestments (see below)|1,948,338|1,778,177|
|Cashdeposits|8,345,397|8,355,241|
||————|————|
||**10,293,735**|**10,133,418**|
||————|————|
||||
|**Market value of listed investments at 1 Jan**|**1,778,177**|**1,803,668**|
||||
|Additions toinvestment portfolio|5,534|10,185|
|Disposals toinvestment portfolio|-|(5,246)|
|Investmentmanager fees|(5,534)|(4,939)|
|NetInvestment gain/(loss)|170,161|(25,491)|
||————|————|
|**Market value of listed investments at 31 Dec**|**1,948,338**|**1,778,177**|
||=======|=======|
|**Listed Investments comprise the following:**|||
||||
|Cashand shortmaturity bonds|-|-|
|Multiclass and other investments|1,948,338|1,778,177|
||————|————|
|**Total listed investments at 31 Dec**|**1,948,338**|**1,778,177**|
||=======|=======|
||||
|**Total Investments are listed in:**|||
|UnitedKingdom|510,465|227,607|
|Overseas|1,437,873|1,550,571|
||————|————|
||**1,948,338**|**1,778,177**|
||=======|=======|
51
## **Investment in subsidiary**
Children with Cancer UK holds 100% of the share capital of Helping Children with Cancer Limited which is a registered company number 04960054. The value of the share capital owned is £100. Helping Children with Cancer Limited raises funds via commercial activities and sponsorship.
The income and expenditure for the year ended 31 December 2021 is as follows:
||**2021**
**£**|**2020**
**£**|
|---|---|---|
|Income|72,225|23,916|
|Administrative expenses|(12,153)|(12,278)|
||————|————|
|**Profit beforegift aid and taxation**|**60,072**|**11,638**|
||========|========|
The balance sheet for the subsidiary as at 31 December 2021 is as follows:
||**2021**
**£**|**2020**
**£**|
|---|---|---|
|Assets|23,740|45,069|
|Liabilities|(23,640)|(44,969)|
||————|————|
|**Reserves**|**100**|**100**|
||========|========|
The charity also holds 100% of the share capital of Children with Cancer Research Limited (09442350) which is currently dormant.
## **13. Trustees’ emoluments**
£250 was paid by Children with Cancer UK for Trustee indemnity insurance (2020 Nil).
## **14. Debtors**
||**2021**
**Group**
**£**|**2021**
**Charity**
**£**|**2020**
**Group**
**£**|**2020**
**Charity**
**£**|
|---|---|---|---|---|
|Amounts duefromsubsidiary undertakings|-|19,680|-|41,369|
|Otherdebtors|855,412|855,412|1,290,708|1,290,708|
|Accruedincome|353,564|340,097|330,469|327,969|
|Prepayments|1,127,410|1,127,410|1,489,068|1,489,068|
||————|————|————|————|
||**2,336,386**|**2,342,599**|**3,110,245**|**3,149,114**|
||========|========|========|========|
52
## **15. Grants to third parties**
||**2021**
**£**|**2020**
**£**|
|---|---|---|
|**Outstanding liabilities at the start of theyear**|**9,902,369**|**10,527,498**|
|Awarded duringtheyear(note 22):|||
|Research into preventionand causes|-|1,570,272|
|Research into treatment and survival|812,027|4,597,501|
|Welfare|1,297,488|1,285,296|
|Raising awareness|1,376|20,750|
||————|————|
|**Total thirdparty grants before adjustments**|**2,110,891**|**7,473,819**|
||||
|Under/overspends and adjustments onprevious grant awards|131,425|(487,058)|
||————|————|
|**Total thirdparty grants**|2,242,316|6,986,761|
||||
|Paid during the year|(2,998,620)|(7,611,890)|
||————|————|
|**Outstanding liabilities at the end of theyear**|**9,146,065**|**9,902,369**|
||========|========|
||||
|Grantsfalling duewithinone year|3,965,171|1,982,298|
|Grantsfalling due after more thanone year|5,180,894|7,920,071|
||————|————|
||**9,146,065**|**9,902,369**|
||=========|=========|
## _**Note**_
There were 11 grant closures with a net value of less than £100 that occurred during the year. There were a further 17 grant closures with a combined value of £877 that occurred during the year. There were 4 grant adjustments £154,560 relating to corrections made to grants awarded in previous financial years.
## **16. Creditors: amounts falling due within one year**
||**2021**
**Group**
**£**|**2021**
**Charity**
**£**|**2020**
**Group**
**£**|**2020**
**Charity**
**£**|
|---|---|---|---|---|
|Accruals and deferredincome|640,172|636,212|613,231|609,631|
|Taxes and socialsecurity|59,770|59,770|57,170|57,170|
||————|————|————|————|
||699,942|695,982|670,401|666,801|
|Grants payable|3,965,171|3,965,171|1,982,298|1,982,298|
||————|————|————|————|
||**4,665,113**|**4,661,153**|**2,652,699**|**2,649,099**|
||========|========|========|========|
## **17. Deferred income**
Deferred income comprises income received in advance for entries to our weekly lottery.
||**2021**
**Group**
**£**|**2021**
**Charity**
**£**|**2020**
**Group**
**£**|**2020**
**Charity**
**£**|
|---|---|---|---|---|
|**Balance as at 1 January 2021**|**52,053**|**52,053**|**51,599**|**51,599**|
||||||
|Amountreleased toincome|(52,053)|(52,053)|(51,599)|(51,599)|
|Amount deferredinyear|56,285|56,285|52,053|52,053|
||————|————|————|————|
|**Balance as at 31 December 2021**|**56,285**|**56,285**|**52,053**|**52,053**|
||========|========|========|========|
53
## **18. Analysis of net assets between funds**
|**As at 31 December 2021**|**2021**
**Group**
**Restricted**
**funds**
**£**|**2021**
**Group**
**Unrestricted**
**funds**
**£**|**2021**
**Group**
**Total funds**
**£**|**2020**
**Group**
**Total funds**
**£**|
|---|---|---|---|---|
|Fixed assets|-|10,293,735|10,293,735|10,133,555|
|Net current assets|-|9,342,381|9,342,381|7,082,177|
|Creditorsfalling due after more thanone year|-|(5,180,894)|(5,180,894)|(7,920,071)|
||————|————|————|————|
|**Net assets at the end of theyear**|**-**|**14,455,222**|**14,455,222**|**9,295,661**|
||=======|=========|=========|=========|
||||||
|**As at 31 December 2020**|**2020**
**Group**
**Restricted**
**funds**
**£**|**2020**
**Group**
**Unrestricted**
**funds**
**£**|**2020**
**Group**
**Total funds**
**£**|**2019**
**Group**
**Total funds**
**£**|
|Fixed assets|-|10,133,555|10,133,555|11,157,521|
|Net current assets|-|7,082,276|7,082,177|6,420,538|
|Creditorsfalling due after more thanone year|-|(7,920,071)|(7,920,071)|(6,676,640)|
||————|————|————|————|
|**Net assets at the end of theyear**|**-**|**9,295,760**|**9,295,661**|**10,901,419**|
||=======|=========|=========|=========|
## **19. Statement of funds**
|**19. Statement of funds**||||||
|---|---|---|---|---|---|
|**Year ended 31 December 2021**|**At the start**
**of the year**
**£**|**Total**
**Income**
**£**|**Total**
**Expenditure**
**£**|**Transfers &**
**Investment**
**gains/losses**
**£**|**At the end**
**of the year**
**£**|
|**Restricted funds**||||||
|Dr Christina Halsey, University of Glasgow. Discovery of
biomarkers and new therapeutic targets for chemotherapy
associatedneurotoxicity|-|500|-|(500)|-|
|Clinical PHD Studentship: Markers of Hypothalamic
Dysfunction in Children with Hypothalamo-Pituitary-Axis
Tumours (HPAT) or PituitaryMaldevelopment|-|64|-|(64)|-|
|Anthony Chalmers - University of Glasgow - Increasing
the susceptibility of neuroblastoma cells to radiotherapy by
targeting glycolysis andlipogenesis|-|500|-|(500)|-|
|Macarena Oporto Espuelas - UCL Great Ormond Street
Institute of Child Health - Identification of novel surface
antigen targets for CAR T cell strategies in paediatric
AcuteMyeloidLeukaemia stemcells.|-|3,651|-|(3,651)|-|
|ProfessorSteve Clifford– INSTINCT-MB|-|231,550|-|(231,550)|-|
|Beads of Courage UK, which helps children in all 110
children’s cancer wards in the UK visualise and articulate
theircancerjourney|-|207,687|(207,687)|-|-|
||————|————|————|————|————|
|**Total Restricted funds**|**-**|**443,952**|**(207,68)**|**(236,265)**|**-**|
|||||||
|Unrestrictedfunds|9,295,761|14,400,497|(9,647,461)|406,425|14,455,222|
||————|————|————|————|————|
|**Total Unrestricted funds**|**9,295,761**|**14,400,497**|**(9,647,461)**|**406,425**|**14,455,222**|
|||||||
|**Total funds**|**9,295,761**|**14,844,449**|**(9,855,149)**|**170,160**|**14,455,222**|
||**========**|**========**|**========**|**========**|**========**|
## _**Note**_
The restricted funds comprise donations that were to be spent on specific causes and projects. All restricted income was either discharged during the year or transferred from restricted back to unrestricted funds. This has occurred when restricted funds were received towards grants that were previously paid out of unrestricted reserves.
54
|**Year ended 31 December 2020**|**At the start**
**of the year**
**£**|**Total**
**Income**
**£**|**Total**
**Expenditure**
**£**|**Transfers &**
**Investment**
**gains/losses**
**£**|**At the end**
**of the year**
**£**|
|---|---|---|---|---|---|
|**Restricted funds**||||||
|BIOMarkers of Ependymomas in Children and
Adolescents (BIOMECA) - Integrated Biological study
within SIOP Ependymoma II trial organised by European
EpendymomaBiology Consortium|-|120|-|(120)||
|Dr Steven Pollard, University of Edinburgh. Genome
editing of human neural stem cells using nuclease-
assisted gene targeting: a tool to uncover the function of
H3F3A mutationsinpaediatric glioma|-|1,000|-|(1,000)||
|Dr Karin Straathof, UCL Institute of Child Health,
Development of GD2-specific Bi-specific T-cell Engagers
(BiTEs)fortreatment of neuroblastoma|-|5,463|-|(5,463)||
|Professor Louis Chesler, Institute for Cancer Research-
Individualising Management of Paediatric Cancer
Treatment- IMPACT|-|4,488|-|(4,488)||
|Harnessing SMAD7 induced transcriptional pathways for
novelanti-leukaemia therapies|-|17,350|-|(17,350)||
|Dr John Bithell, University of Oxford- Preservation and
analysis of pathology records and family histories of
children withcancer|-|1,500|-|(1,500)||
|Functions of DOT1L and H3K79 methylation in MLL-
rearrangedleukaemia|-|3,895|-|(3,895)||
|Safety enhanced CAR TcelltherapyforpaediatricAML|-|13,365|-|(13,365)||
|John Anderson - UCL Great Ormond Street Institute of
Child Health - Pilot to developCRISPR library screen for
enhanced function of G-D-T cells in paediatric solid
cancers.|-|14,500|(14,500)|-||
|Defne Saatci - UCL Great Ormond Street Institute of Child
Health - Investigating Late Effects of Surviving Childhood
Cancer|-|5,000|(5,000)|-||
|Beads of Courage UK, which helps children in all 110
children’s cancer wards in the UK visualise and articulate
theircancerjourney|-|207,687|(207,687)|-||
|CLIC Sargent|-|500|-|(500)||
|Children’s Leukaemia Trust. Restricted for research into
and trainingfor Leukaemia andLymphomainchildren|527,344|-|(527,344)|-|-|
||————|————|————|————|————|
|**Total Restricted funds**|**527,344**|**274,868**|**(754,531)**|**(47,681)**|**-**|
|||||||
|Unrestrictedfunds|10,374,075|13,478,137|(14,587,641)|22,190|9,295,761|
||————|————|————|————|————|
|**Total Unrestricted funds**|**10,374,075**|**13,478,137**|**(14,587,641)**|**22,190**|**9,295,761**|
|||||||
|**Total funds**|**10,901,419**|**13,762,005**|**(15,342,172)**|**(25,491)**|**9,295,761**|
||**========**|**========**|**========**|**========**|**========**|
## **20. Related Party Transactions**
There have been no other related party transactions during the year other than those with the trading subsidiary.
A management fee of £5,000 (2020: £5,000) has been charged to the trading subsidiary for use of the charity’s trademarks and a further £3,520 (2020: £3,645) for the use of charity staff (calculated on the basis of time charged to subsidiary activity by the employee). As at 31st December 2021, £19,680 (2020: £41,369) owed to the charity from the trading subsidiary.
55
## **21. Financial Instruments**
The financial statements include the following in respect of items:
||**2021**
**£**|**2020**
**£**|
|---|---|---|
|Financialassetsmeasured atfair value|1,948,338|1,778,177|
||||
||**2021**
**£**|**2020**
**£**|
|The entity’s income, expense, gains and losses in respect of
financial instruments are summarised below:|||
||||
|Total interestincomefor financialassetsheld atfair value|(48,672)|129,182|
## **22. Grants to third parties**
|**Grants awarded to third parties during the year**|**Research**
**into**
**prevention**
**and causes**
**2021**
**£**|**Research**
**into**
**treatment**
**2021**
**£**|**Raising**
**Awareness**
**2021**
**£**|**Welfare**
**2021**
**£**|**Total 2021**
**£**|
|---|---|---|---|---|---|
|Birmingham Women’s and Children’s Hospital Charity - The
purchase of a high-throughput sequencing machine (NovaSeq
6000)||||1,072,488|**1,072,488**|
|INSTINCT-MB: Strategic implementation of novel combination
therapeutics for high-risk medulloblastoma||712,027|||**712,027**|
|Beads of Courage - 2021||||225,000|**225,000**|
|Bioinformatics support for primary bone cancer plus other
childhood cancer studies||100,000|||**100,000**|
|British Neuro-Oncology Society Annual Meeting 2021|||1,200||**1,200**|
|International Family Nursing Association Meeting 2021|||176||**176**|
|**Total grants to third parties awarded in the year**|**-**|**812,027**|**1,376**|**1,297,488**|**2,110,891**|
|Grant closures and adjustments|(4,428)|1,294|10,559|124,000|131,425|
|**Total grants to third parties**|**(4,428)**|**813,321**|**11,935**|**1,421,488**|**2,242,316**|
## _**Note**_
There were 11 grant closures with a net value of less than £100 that occurred during the year. There were a further 17 grant closures with a combined value of £877 that occurred during the year. There were 4 grant adjustments of £154,560 relating to corrections made to grants awarded in previous financial years.
56
|**Grants awarded to third parties in 2020**|**Research**
**into**
**prevention**
**and causes**
**2020**
**£**|**Research**
**into**
**treatment**
**2020**
**£**|**Raising**
**Awareness**
**2020**
**£**|**Welfare**
**2020**
**£**|**Total 2020**
**£**|
|---|---|---|---|---|---|
|Cancer Research UK–Children with Cancer UK Innovation
Awards|1,295,725|1,204,275|||**2,500,000**|
|Teenage Cancer Trust: Emergency CoronavirusAppeal||||1,000,000|**1,000,000**|
|Mike Hawkins - University of Birmingham - Establish a
comprehensive surveillance system for adverse health
outcomes in British survivors of childhood, teenage and young
adult cancer||349,982|||**349,982**|
|Kathy Pritchard-Jones - UCL Great Ormond Street Institute of
Child Health - International benchmarking of childhood cancer
survivalby stage||349,747|||**349,747**|
|Chris Jones - Institute of Cancer Research - Evolutionary
dynamics of MEK inhibitor sensitivity and resistance in diffuse
midline glioma||349,393|||**349,393**|
|Steve Clifford - Newcastle University - SMILE: An
International network for Medulloblastoma Survivorship and
Late-Effects||348,783|||**348,783**|
|Sam Behjati - Wellcome Sanger Institute - Developmental
states of localised and metastatic osteosarcoma cells – a
knowledge bank for novel biomarkers and therapeutic
approaches||349,419|||**349,419**|
|Beads ofCourage- 2020||||285,296|**285,296**|
|Anthony Chalmers - University of Glasgow - Increasing the
susceptibility of neuroblastoma cells to radiotherapy by
targeting glycolysis andlipogenesis||249,774|||**249,774**|
|Veronica Kinsler - UCL Great Ormond Street Institute of Child
Health - Identification of new therapies for melanoma in
congenital melanocytic naevi - a universally fatal paediatric
tumour||249,756|||**249,756**|
|Marc Mansour - UCL Cancer Institute - CCR9 as a novel
immunotherapy target in T-cell acute lymphoblastic leukaemia
(T-ALL)||249,325|||**249,325**|
|Macarena Oporto Espuelas - UCL Great Ormond Street
Institute of Child Health - Identification of novel surface antigen
targets for CAR T cell strategies in paediatric Acute Myeloid
Leukaemia stemcells.||220,000|||**220,000**|
|Defne Saatci - UCL Great Ormond Street Institute of Child
Health - Investigating Late Effects of Surviving Childhood
Cancer||216,963|||**216,963**|
|Julie Irving - Newcastle University - Optimising the use of
repurposed drugs to improve the treatment of children with
ALL||213,259|||**213,259**|
|Schuz - International Agency for Research on Cancer - Dr
JoachimSchüz, CLICData Coordinating Center - Extension|95,060||||**95,060**|
|International Agency for Research on Cancers - IARC
Postdoctoral Fellowship|81,933||||**81,933**|
|Ian Fairlie - NA - Report: The effects of Low Level Ionising
Radiation Exposure especially regarding child and young
personcancer incidence|78,588||||**78,588**|
|Chris Jones - Institute of Cancer Research - INSTINCT interim
funding|10,000|58,380|||**68,380**|
|Claire Clarkin - University of Southampton - Developing 3-
dimensional multicellular models ofosteosarcoma||49,984|||**49,984**|
|John Anderson - UCL Great Ormond Street Institute of Child
Health - Pilot to developCRISPR library screen for enhanced
functionofG-D-Tcellsinpaediatric solid cancers.||49,930|||**49,930**|
|Faith Gibson - University of Surrey - PersonAlised
survivorship care: customising supporT towards unmet
psycHosocial needsinyoung peoplewithcancer(PATHstudy)||48,202|||**48,202**|
|Steve Clifford - Newcastle University - INSTINCT interim
funding||21,316|||**21,316**|
|BCRT - Bone Cancer Research Trust|||20,000||**20,000**|
57
|**Grants awarded to third parties in 2020 - Continued**|**Research**
**into**
**prevention**
**and causes**
**2020**
**£**|**Research**
**into**
**treatment**
**2020**
**£**|**Raising**
**Awareness**
**2020**
**£**|**Welfare**
**2020**
**£**|**Total 2020**
**£**|
|---|---|---|---|---|---|
|John Murphy - University of Westminster - A pilot Investigation
of the ZFP36L1 protein as a candidate therapeutic target in
osteosarcoma cells||14,013|||**14,013**|
|International Agency for Research on Cancers - IARC
Postdoctoral Fellowship|5,154||||**5,154**|
|Raoul Reulen - University of Birmingham - Pilot study to
investigate self-reported health behaviours in survivors of
teenage and young adult cancer||5,000|||**5,000**|
|M Niklison - Queen Mary University of London - Paul
O’Gorman Post-doctoral Research Fellowship - Metabolic
analysis of the tumour suppressor protein p73 in
medulloblastoma|3,812||||**3,812**|
|Becci Pearson - British Neuro-Oncology Society - BNOS
Sponsorship|||750||**750**|
|**Total grants to third parties awarded in the year**|**1,570,272**|**4,597,501**|**20,750**|**1,285,296**|**7,473,819**|
|**Underspends on previous grant awards**||||||
|Tariq Enver - UCL Cancer Institute - Dissecting the causative
and collaborating roles of candidate genetic mutations in the
pathogenesis ofchildhoodALL|(293)||||**(293)**|
|Dr Steven Pollard, University of Edinburgh. Genome editing of
human neural stem cells using nuclease-assisted gene
targeting: a tool to uncover the function of H3F3A mutations in
paediatric glioma|(455)||||**(455)**|
|Waseem Qasim - UCL Great Ormond Street Institute of Child
Health - T cell receptor gene therapy: Novel strategies for
children withcancerusing engineered cord bloodTcells||(788)|||**(788)**|
|Professor Chris Jones, Institute of Cancer Research, The role
of histone H4K20 methylation in paediatric glioblastoma and
DIPG|(2,648)||||**(2,648)**|
|Dr Marc Tischkowitz, University of Cambridge, Investigating
microRNA processing genes in rhabdomyosarcomas and other
DICER1-related childhood tumours|(2,661)||||**(2,661)**|
|Professor Robert Mairs, University of Glasgow. Exploitation of
the elevated metabolic activity of cancer cells for combination
withtargetedradiotherapy of neuroblastoma||(4,997)|||**(4,997)**|
|Dr Suzanne Turner, University of Cambridge, CRISPR-based
genome-wide knockout and overexpression screens to identify
acquired resistance mechanisms to ALK inhibition in
neuroblastoma||(6,511)|||**(6,511)**|
|Dr Faith Gibson - Great Ormond Street Hospital - Evaluating
HELP: an intervention for parents sharing information about
leukaemiawiththeirchild.|||(13,999)||**(13,999)**|
|Katherine Clesham - UCL Great Ormond Street Institute of
Child Health - Targeting c-MYB in acute leukaemia through
drugrepositioning||(18,722)|||**(18,722)**|
|Immunotherapy with CD19ζ gene-modified EBV-specific CTLs
after stem cell transplantation in children with high-risk acute
lymphoblasticleukaemia||(22,420)|||**(22,420)**|
|Dr Elizabeth Calton, The Institute of Cancer Research,
Mutational dynamics and their effect on chemoresistance and
metastasis in a genetically engineered mouse model of
relapsedneuroblastoma||(25,777)|||**(25,777)**|
|Dr Patrick Hales, Institute of Child Health, University College
London. Advanced magnetic resonance imaging techniques
for in vivo assessment of tumour heterogeneity, risk factor, and
treatmentresponseinpaediatric cancer||(115,379)|||**(115,379)**|
|Professor Pamela Kearns. Programme grant: UK ALL 2011||(272,408)|||**(272,408)**|
|**Total grants to third parties**|**1,564,215**|**4,130,499**|**6,751**|**1,285,296**|**6,986,761**|
58
**Every day 12 children and young people are diagnosed with cancer in the UK.**
**Of those 12, two will not survive**
**8 out of 10 young childhood cancer patients can be successfully treated thanks to vital, specialist research we helped fund.**
**Our aims are to determine the causes, find cures and provide care for children with cancer. We are united by a common goal – to save and improve young lives.**
**We fund Research We fund Welfare We raise Awareness**
Children with Cancer UK Registered Office 51 Great Ormond Street London WC1N 3JQ
59